Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2021 Dec 3;17(12):e1009947. doi: 10.1371/journal.pgen.1009947

bfc, a novel serpent co-factor for the expression of croquemort, regulates efferocytosis in Drosophila melanogaster

Qian Zheng 1,#, Ning Gao 1,#, Qiling Sun 1,#, Xiaowen Li 1, Yanzhe Wang 1, Hui Xiao 1,*
Editor: Estee Kurant2
PMCID: PMC8673676  PMID: 34860835

Abstract

Efferocytosis is the process by which phagocytes recognize, engulf, and digest (or clear) apoptotic cells during development. Impaired efferocytosis is associated with developmental defects and autoimmune diseases. In Drosophila melanogaster, recognition of apoptotic cells requires phagocyte surface receptors, including the scavenger receptor CD36-related protein, Croquemort (Crq, encoded by crq). In fact, Crq expression is upregulated in the presence of apoptotic cells, as well as in response to excessive apoptosis. Here, we identified a novel gene bfc (booster for croquemort), which plays a role in efferocytosis, specifically the regulation of the crq expression. We found that Bfc protein interacts with the zinc finger domain of the GATA transcription factor Serpent (Srp), to enhance its direct binding to the crq promoter; thus, they function together in regulating crq expression and efferocytosis. Overall, we show that Bfc serves as a Srp co-factor to upregulate the transcription of the crq encoded receptor, and consequently boosts macrophage efferocytosis in response to excessive apoptosis. Therefore, this study clarifies how phagocytes integrate apoptotic cell signals to mediate efferocytosis.

Author summary

The swift removal of apoptotic cells by specialized cells such as macrophages (a subtype of white blood cells), is a critical event in shaping tissues during the development of all multicellular organisms, from worms to humans. Defects in the removal of dying cells, a process known as the clearance of apoptotic cells (ACs), can contribute to the development of autoimmune disorders such as systemic Lupus erythematosus (SLE) and neurodegenerative diseases like Alzheimer’s disease. Croquemort (Crq), a Drosophila CD36-related receptor, is required for the recognition and engulfment of ACs in macrophages. In this study, via transcriptomic analysis and RNAi screening, we discovered 12 genes required for the clearance of ACs in macrophage-like S2 cells in Drosophila. In particular, we identified a novel gene, bfc (booster for croquemort), involved in apoptotic cell clearance via the specific regulation of the crq transcriptional expression. We demonstrate that the GATA transcription factor Serpent (Srp) directly binds to the crq promoter, while Bfc strengthens this binding via its interaction with the Srp zinc finger domain. Therefore, we propose a model in which Bfc cooperates with Srp to enhance the expression of crq and subsequently induce apoptotic cell clearance in Drosophila melanogaster.

Introduction

Apoptosis is a developmentally programmed cell death process in multicellular organisms essential for the removal of excessive or harmful cells [1]; whereby apoptotic cells (ACs) are swiftly removed by phagocytes to prevent the release of toxins and induction of inflammation [2], a process crucial for organ formation, tissue development, homeostasis, and normal immunoregulation. In fact, defects in AC clearance (efferocytosis) [3,4] can lead to the development of various inflammatory and autoimmune diseases [5]. During efferocytosis, the effective clearance of ACs is accomplished through the recognition and binding of engulfment receptors or bridging molecules on the surface of phagocytes to “eat me” signals exposed on the surface of ACs [610]. After receptor activation, downstream signals trigger actin cytoskeleton rearrangement and membrane extension around the ACs to form phagosomes. Finally, mature phagosomes fuse with lysosomes to form phagolysosomes, where the internalized ACs are ultimately digested and cleared [11,12].

Since efferocytosis is conserved throughout evolution, it has been studied not only in mammals but also in Drosophila melanogaster. Of note, in D. melanogaster, ACs are removed by non-professional phagocytes, such as epithelial cells [13] and professional phagocytes, such as macrophages and glial cells [4]. Importantly, Drosophila macrophages perform similar functions to those of mammalian macrophages; they participate in both the phagocytosis of ACs and pathogens [4,14]. Several engulfment receptors have been identified as key players in the recognition and removal of ACs in Drosophila. Franc and colleagues first characterized Croquemort (Crq), a Drosophila CD36-related receptor required by macrophages to engulf ACs [8,15]. Additionally, Draper (Drpr, a homolog of CED-1/MEGF10) also mediates AC clearance in both glia and macrophages; JNK signaling plays a role in priming macrophages to rapidly respond to injury or microbial infections [16,17]. Of note, Drpr and its adapter Dmel\Ced-6 (GULP homolog) also seemed important for axon pruning and the engulfment of degenerating neurons by glial cells [18,19]. The Src tyrosine kinase Src42A (Frk homolog) promotes Drpr phosphorylation and its association with another soluble tyrosine kinase, Shark (ZAP70 homolog), which in turn activates the Drpr pathway [20]. In addition to Drpr, Six-Microns-Under (SIMU) [10] and integrin αPS3 [21] contribute to efferocytosis. SIMU, a Nimrod family cell surface receptor [22], functions upstream of Drpr to mediate the recognition and clearance of ACs as well as of non-apoptotic cells at wound sites [10,23] through the recognition of phosphatidylserine (PS). Importantly, the transcriptional factor Serpent (Srp), a GATA factor homolog [24,25], was recently found to be required for the efficient phagocytosis of ACs in the context of Drosophila embryonic macrophages and acted via the regulation of SIMU [10], Drpr, and Crq [26].

Searching for other genes required for efferocytosis, here we performed transcriptomic analysis (RNA-seq) and RNAi screening, and discovered 12 genes required for AC clearance in Drosophila S2 cells. In particular, we identified a novel gene, bfc (booster for croquemort), involved in efferocytosis that encodes a specific regulatory factor for the crq transcriptional expression, both in vitro and in vivo. Importantly, we demonstrate that the GATA factor Srp directly binds to the crq promoter, while Bfc strengthens this binding by interacting with the Srp zinc finger domain. Therefore, we propose a model in which Bfc cooperates with Srp to enhance crq expression and subsequently induce efferocytosis in D. melanogaster.

Results

RNA-seq discloses 48 genes with expression patterns comparable to that of crq in S2 cells co-incubated with ACs

The expression of crq increases when apoptosis begins, whereas the absence of ACs results in decreased Crq levels [8]. To confirm this, we used Drosophila S2 cells (phagocytic cells with macrophage-like lineage derived from late embryonic stages) [27] in the presence or absence of ACs as an in vitro model of efferocytosis and measured the relative expression of crq. The ACs were prepared as previously described [28]; we confirmed that ACs were successfully obtained via Annexin V/PI staining (S1A and S1B Fig) and the detection of cleaved Dcp1 (S1C Fig). Of note, we analyzed the crq mRNA levels in S2 cells incubated with ACs over a course of 24 h (2, 4, 6, 8, 10, 12, 18, and 24 h; versus 0 h S2 cells without ACs as the control), and found that the expression of crq increased significantly at 4 h, remained high after 8 h, dropped sharply at 10 h, and remained at relatively low levels for the remaining time (Fig 1A). Therefore, we chose three time points (0, 6, and 12 h) to detect the Crq protein levels. Western blotting showed that the trend in Crq protein accumulation matched that of the above-mentioned transcriptional patterns in S2 cells co-incubated with ACs (Fig 1B and 1C). Importantly, the decreased Crq protein expression after 12 h incubation with ACs did not significantly affect the phagocytic activity of S2 cells; in fact, efferocytosis at 12 h was higher than that in S2 cells incubated with ACs for only 6 h (Fig 1D and 1E). Overall, our results show that the expression of Crq is induced by ACs at both the transcriptional and translational levels.

Fig 1. The upregulated transcripts after the incubation of S2 cells with ACs.

Fig 1

A. The crq mRNA levels were quantified by quantitative RT-PCR, and normalized to those of Rpl32 mRNA. B. Western blot analysis of Crq protein levels in S2 cells at 0, 6, and 12 h after the addition of ACs. Actin was used as the loading control. C. Quantification of the Crq protein levels shown in (B) after normalization to those of Actin, n = 3. D. AC efferocytosis by S2 cells at 0, 6, and 12 h. Live cells are shown in blue, and engulfed FITC-labeled ACs are shown in green. Scale Bars = 50 μm. E. Graph summarizing the quantification of the data in (D). The error bars represent the SEM. F. A heatmap of the 50 transcripts that showed similar expression patterns as of crq. Each column represents an independent sample. The color code and density represent the level of regulation: the red color defines genes with up-regulated expression, while the blue color defines genes with down-regulated expression. G. Venn diagram showing the differentially regulated transcripts after the addition of ACs: expression levels of 783, 1111 and 2232 transcripts were up-regulated in 6 h versus 0 h, 6 h versus 12 h, and 12 h versus 0 h comparisons, respectively. Statistical analysis was performed using the one-way ANOVA and the p values are denoted.

Since Crq is a well-known engulfment receptor, it is reasonable to consider that genes with expression patterns comparable to that of crq expression in S2 cells-ACs co-cultures may also be associated with efferocytosis. Therefore, next, we performed a transcriptomic analysis of S2 cells incubated with ACs for 6 h and 12 h and compared the results with those obtained using S2 cells not exposed to ACs using the Illumina HiSeq 2500 [29] platform. After filtering the low-quality reads and removing the rDNA or tRNA reads, we considered the genes with q < 0.05, and |log FC| ≥0.4 (FC = fold change) as differentially expressed. We obtained 1381, 1212, and 3620 differentially expressed genes from the comparisons performed at 6 h versus 0 h, 12 h versus 0 h, and 6 h versus 12 h, respectively (S1 Data). Interestingly, after setting the significance cut-off value to p< 0.05, and the threshold crq expression levels to > 1.8 or > 1.4 (6 h or 12 h, respectively versus 0 h), 50 genes were found to have a similar expression trend as of crq (Fig 1F and 1G), including pseudogene CR43687. Of note, S2 cells displayed changes in multiple transcriptional programs (Fig 1F), including the increased expression of innate immunity genes and genes involved in efferocytosis, in line with previously reported data [30].

CG9129 is involved in efferocytosis and regulates crq expression in S2 cells

To validate the RNA-seq data, we performed quantitative real time RT-PCR (qPCR) to test the status of representative genes selected across a range of expression levels (Fig 1 and S1 Table). After qPCR validation in three independent experiments, we identified 24 genes whose expression patterns were highly similar to that of crq (Fig 2A and 2B). As necrosis may occur during the late stage of apoptosis, these genes may be upregulated by ACs or necrotic cells. Therefore, we performed RNAi suppression by individually targeting each gene in S2 cells (S1D Fig), and then incubated the RNAi treated cell lines with ACs to measure their efferocytosis capacity. Compared to mock RNAi treatments (34.4%) and the Rab5 RNAi positive control (13.2%), 12 RNAi treatments led to reduced efferocytosis efficiency (Fig 2C).

Fig 2. CG9129 is involved in efferocytosis and regulates crq expression in vitro.

Fig 2

A and B. The transcription levels of differentially expressed genes determined by the transcriptomic analysis were validated by qPCR in S2 cells incubated with ACs for 0, 6, and 12 h. Twenty-four genes showed expression patterns similar to that of crq. The data were collected from three independent experiments; 0 h S2 cells were used as the control. The asterisks above the column of the 6 h time-point denote a significantly higher gene expression than that detected at 0 h. The asterisks above the column of the 12 h time-point denote a significantly lower gene expression than that detected at 6 h. C. Efferocytosis efficiency of RNAi-treated S2 cells after 6 h co-incubation with ACs. Each of the identified 24 genes was knocked down individually. The data are representative of three independent experiments. Significant differences were observed in comparison with mock RNAi-treated S2 cells (negative control), or crq and Rab5 RNAi-treated S2 cells (positive controls). D. The crq mRNA levels were quantified by qPCR in RNAi-treated S2 cells showing decreased efferocytosis during 6 h incubation with ACs. The data are relative to the expression determined in mock RNAi-treated S2 cells. E. The relative crq mRNA levels were also quantified by qPCR in control, CG9129 knockdown, and CG30172 knockdown S2 cells in the absence (0 h) or presence of ACs (6 h incubation). Statistical analysis was performed using the two-way ANOVA (A-B, E) or one-way ANOVA (C-D).

We then assessed whether these 12 genes affected AC clearance via regulating the expression of crq. Interestingly, we found that RNAi treatments targeting CG9129 and CG30172 lead to decreased crq expression (by 30% and 47%, respectively; Fig 2D). Importantly, CG9129- and CG30172-targeted RNAi suppression did not affect the crq mRNA levels in S2 cells in the absence of ACs, indicating that CG9129 and CG30172 specifically regulate the expression of crq in response to stimulation by ACs (Fig 2E). Furthermore, the overexpression of CG9129 was sufficient to upregulate the crq mRNA expression in the presence of ACs (S2A Fig). Interestingly, Crq was also shown to regulate the transcription of CG9129 (S2 Fig), suggesting a positive feedback mechanism between the transcription of CG9129 and crq in efferocytosis. Of note, CG9129 encodes a low-complexity protein of unknown function, while CG30172 was previously described as the insect odorant-binding protein A10, a member of the ejaculatory bulb-specific protein 3 superfamily [31]. Therefore, we decided to focus our study on the protein of unknown function (encoded by CG9129), here after named Booster for Crq (Bfc).

crq expression is regulated by Bfc in vivo

The first wave of apoptosis in Drosophila begins at stage 11 (approximately 7 h after egg laying) of embryogenesis at 25°C [32]. The macrophages originate from the cephalic mesoderm and spread throughout the embryo. Similar to the pattern of apoptosis, Crq protein is expressed in hemocytes/macrophages from late stage 11 of embryogenesis [15], consistent with its function as an engulfment receptor. We observed that reduced bfc levels resulted in defective efferocytosis in vitro (Fig 3A). To understand whether the relationship between Bfc and crq in the context of efferocytosis also existed in vivo, we generated a bfcko mutant using CRISPR/Cas9 technique. Significantly, the sequencing results showed early termination of the predicted Bfc protein (Fig 3B); additionally, qPCR and western blot analyses confirmed successful establishment of a null allele mutant (Fig 3C and 3D). Of note, the bfcko mutants were viable and lacked obvious developmental defects. Next, we collected wild-type and bfcko embryos from stages 7 to 14 and analyzed the crq and bfc expression by qPCR. As anticipated, the bfc and crq mRNA levels were upregulated in wild-type embryos as apoptosis occurred at stages 9 and 11 (S3A and S3B Fig). On the contrary, the crq mRNA levels did not increase in bfcko embryos at stage 11 (S3C Fig); however, the levels of Crq protein increased in stage 11 bfc-null embryos (S3D and S3E Fig). One possible explanation for these discrepant results is that some translated Crq may undergo post-translational modifications in bfcko embryos at stage 11 to become stable. Additionally, while the Crq protein levels increased from stages 12 to 14 in wild-type embryos, bfcko embryos failed to upregulate the Crq protein expression at the corresponding stages (S3D and S3E Fig). To further confirm that the upregulation of crq and bfc was induced by ACs, we also quantified the crq and bfc mRNA levels in stage 10 to 13 H99 embryos (in which apoptosis does not occur); importantly, both expression levels were lower in H99 compared to those in the wild type embryos and did not increase during embryonic development (S3F Fig). Altogether, these results suggest that the crq expression is impacted by Bfc during AC clearance in Drosophila embryogenesis.

Fig 3. bfc in macrophages and S2 cells is required for efficient efferocytosis.

Fig 3

A. Confocal images showing AC efferocytosis by control-, crq RNAi-, and bfc RNAi-treated S2 cells (the efferocytosis efficiency is quantified in Fig 2C). Live cells are shown in blue, while cells that engulfed FITC-labeled ACs are shown in green. Scale Bars = 50 μm. B. Schematic diagram of the bfcko mutant created by CRISPR/Cas9. The exon is denoted as a blue box, and the transcriptional direction is highlighted with an arrow. The double slash represents the Cas9 cutting site. The red marked amino acids represent the mutated sequence. “*” represents the introduced termination codon. C. The bfc mRNA levels were quantified by qPCR in w1118 and bfcko mutant samples. D. The Bfc protein levels were also quantified via western blotting in w1118 and bfcko mutant samples. Actin was used as the loading control. E. AO-stained wild-type, bfcko mutant, and bfcko mutant re-expressing UAS-bfc (under the control of a crq-Gal4 driver) stage 13 embryos. The insets represent the higher-magnification views of the demarked AO-stained corpses. Scale bar = 20 μm. F. Confocal stacks of the head region of stage 13 embryos on the lateral view. Macrophages and apoptotic bodies were stained with anti-Crq (green) and anti-Dcp1 (magenta) antibodies, respectively in wild-type, bfcko mutant, and bfcko; crqGal4>UAS-bfc embryos, which were imaged using the enhanced similarly to show macrophages. Scale bar = 20 μm. G. Graph showing the mean PI ± SEM for each genotype showed in (F). H. Western blot analysis of the Crq and Bfc protein levels in stage 13 embryos of w1118, bfcko mutant, and bfcko mutant re-expressing UAS-bfc (under the control of a crq-Gal4 driver). Actin was used as the loading control. I-J. Quantification of the Crq and Bfc protein levels in (H) after normalization to the Actin levels; n = 3. Statistical analysis was performed using the student’s t-test(C) and one-way ANOVA(G, I, J).

In addition to Crq, Drpr and SIMU are the other two phagocytic receptors expressed in Drosophila embryonic macrophages as well as in “non-professional” phagocyte glia and the ectoderm [10]. To ascertain whether bfc specifically regulates crq expression in vivo, we measured the parallel expression of drpr and simu. We observed that the drpr mRNA expression was upregulated in S2 cells co-incubated with ACs (S3G Fig), and no significant decrease in the drpr expression was detected in Bfc knockdown S2 cells (S3H Fig). Importantly, the decreased expression of Crq in bfcko mutant embryos was consistent with our in vitro results; of note, the loss of bfc specifically impacted the crq expression (and not the drpr expression) both in S2 cells and Drosophila embryos (S3H and S4A Figs). In addition, the mRNA levels of drpr, crq, and simu in srp mutant embryos showed a decreased expression, which was consistent with the results reported in a previous study (S4A Fig)[26]. However, drpr and simu expression was not decreased in bfcko mutant embryos (S4A Fig). Taken together, these results show that in vivo, the expression of Bfc, Crq, and Drpr is regulated by the presence of ACs, but only the upregulation of Crq expression is mediated by Bfc.

Macrophages require Bfc for efficient efferocytosis

Compared with control-treated S2 cells, bfc RNAi-treated S2 cells engulfed much fewer ACs, exhibiting a similar efferocytosis defect as crq RNAi-treated S2 cells. To address whether Bfc also impacts efferocytosis in vivo, first we looked at macrophage development by performing acridine orange (AO) staining, as AO can stain all apoptotic cells engulfed by macrophages in the Drosophila embryo [28]. We found clustered AO-stained ACs in wild-type embryos. Importantly, bfcko mutant embryos showed comparable results, suggesting that the Bfc knockout did not affect the development of macrophages (Fig 3E). In addition, the number of macrophages and ACs in the embryos was quantified using Crq (macrophage marker) and Drosophila Dcp1 (AC marker) staining. We found that macrophages developed normally and migrated throughout in stage 13 embryos, and there was no apparent difference in the number of ACs, further supporting the hypothesis that Bfc knockout does not affect macrophage development (S4B and S4C Fig). To quantify the engulfment of apoptotic bodies by macrophages, we also counted the number of apoptotic particles per macrophage, termed as the “phagocytic index”(PI) [33]. We observed that wild-type macrophages efficiently engulfed ACs, with a PI of 2.74 ± 0.1, while bfcko mutant macrophages showed reduced AC engulfment, with a lower PI of 1.78 ± 0.04 (35% reduction) (Figs 3F,3G, S5A and S5D). This difference was also observed in the context of a Srp-Gal4,UAS-GFP marker model; control embryos showed ACs mostly inside GFP-positive macrophages (S5B Fig), while in bfcko mutant embryos, most apoptotic particles (detected in lower abundance) were outside GFP-positive macrophages (S5C and S5D Fig). Moreover, we detected decreased expression of Crq in bfcko mutant embryos, suggesting that the downregulated Crq expression in the absence of bfc leads to defective AC clearance (Fig 3H, 3I and 3J). Importantly, to prove that the obtained phenotype was indeed dependent on the bfc knockout, we generated a transgenic line encoding the full-length cDNA isoform UAS-bfc and expressed bfc in bfcko mutant macrophages driven by the macrophage-specific crq-Gal4 promoter. We observed that the Bfc expression was restored in mutant macrophages and fully rescued the AC clearance defect (PI of 2.52 ± 0.25), as supported by the presence of several apoptotic bodies within the majority of complemented macrophages (Fig 3F and 3G). Of note, the restoration of Crq and Bfc expression levels to those quantified in wild-type cells was also observed (Fig 3H, 3I and 3J). Finally, as an alternative approach to confirm the role of Bfc in efferocytosis, we used a mutant from Bloomington Drosophila Stock Center with a MiMIC insertion [34] in the first exon region of the bfc locus, bfcMI02020. This insertion produced a potentially strong loss-of-function allele: the bfc expression levels were extremely low levels compared to those detected for the wild-type allele (S6A Fig). Importantly, homozygous bfcMI02020 macrophages in stage 13 embryos showed a significantly impaired phagocytic ability with a PI of 2.0 ± 0.4, and the transgenic Bfc expression driven by a macrophage-specific crq-Gal4 promoter fully rescued the AC clearance defects with a PI of 2.8 ± 0.3, thus supporting the hypothesis that Bfc is required for efferocytosis in vivo (S6B and S6C Fig). Of note, the restoration of Crq expression in bfcko macrophages to the levels observed in wild-type cells also completely rescued the AC clearing defect, with a PI of 2.9 ± 0.44 (S6D and S6E Fig), highlighting the importance of the cross-talk between Bfc and Crq in efferocytosis. Altogether, our results demonstrate that in embryonic macrophages, Bfc regulates the expression of Crq, and is required for an efficient efferocytosis in vivo.

Bfc physically interacts with the GATA factor Srp

As Bfc was shown to regulate crq expression at the transcriptional level, we initially hypothesized that it encodes a transcription factor. However, bioinformatics analysis showed that Bfc is an uncharacterized protein consisting of 251 amino acids with a predicted molecular weight of 29 kD, and without a conserved transcription factor domain. Significantly, protein sequence alignment showed no homolog of Bfc in vertebrates. Therefore, to clarify the function of Bfc in efferocytosis, next we examined the Bfc localization in embryonic macrophages via immunofluorescence staining with anti-Bfc and anti-Crq antibodies. Expectedly, our results revealed Bfc protein localization in macrophages (Fig 4A). Interestingly, the subcellular localization analysis revealed that Bfc-GFP fusion proteins were predominantly localized in the nucleus of S2 cells (Fig 4B). Of note, anti-Bfc staining also showed that endogenous Bfc was localized in the nucleus of both S2 cells and macrophages (Fig 4B’, 4B” and 4B”‘). Since Bfc regulates the transcriptional expression of crq, and localized in the nucleus, we hypothesized that Bfc acts as a co-factor of (a) crq-specific transcription factor(s).

Fig 4. bfc is expressed in embryonic macrophages, and physically interacts with the GATA factor Srp.

Fig 4

A. Macrophages of stage 13 w1118 and bfcko embryos were stained with anti-Crq (magenta) and anti-Bfc (green) antibodies. Scale bar = 20 μm. B. Representative fluorescence pictures of the Bfc-GFP expression in S2 cells; B’-B”‘. Anti-Bfc (green) stained S2 cells (B’); macrophages (showed Mp for short in figure) isolated from w1118 larvae (B”) and bfcko larvae (B”‘); the nuclei were stained using Hoechst 33342 (blue). Scale bar = 5 μm. C. Yeast two-hybrid assays to detect the interaction of Bfc (Bait) with Srp (Prey). Different concentrations of the labeled yeast transformants were grown on SD-Trp-Leu-His plates. D. Crude protein extracts from blank S2 cells, transiently transfected S2 cells expressing Bfc-Flag, and HA-Srp or HA-Srp alone were immunoprecipitated with anti-Flag magnetic beads. WB detection was performed using anti-Flag and anti-HA antibodies. E-E’. Anti-Srp (green) stained control S2 cells as well as bfc RNAi-treated S2 cells; the nuclei were stained using Hoechst 33342 (blue). Scale bar = 5 μm.

Previous studies have demonstrated that several signaling pathways, such as d-JNK, PI3K, and insulin signaling, regulate the expression of the engulfment receptor Drpr [3537]. In particular, Serpent (Srp), a critical transcriptional regulator of macrophage development, is required for apoptotic cell clearance by embryonic macrophages through the regulation of the expression of SIMU, Drpr, and Crq [26]. Therefore, to understand whether Bfc serves as a cofactor of Srp, we used yeast two-hybrid interaction analysis. Importantly, we found that Bfc indeed interacted with Srp in yeast cells (Fig 4C). We further confirmed that Bfc interacts with Srp in S2 cells by performing co-immunoprecipitation experiments using Flag-tagged Bfc and HA-tagged Srp expressing cells (Fig 4D). Of note, the knockdown of Bfc did not impact Srp localization (Fig 4E and 4E’), strongly suggesting that Bfc serves as a cofactor of the Srp-mediated transcriptional regulation.

Bfc and Srp act together to regulate crq expression in the context of efferocytosis

Our results clearly showed that Bfc physically interacts with Srp. To address whether the Bfc-Srp binding exerted the physiological effects observed in vivo, we examined the transcriptional and translational relationship between bfc and srp expression. To this end, we first detected the Crq transcript and protein levels in bfcko, srp mutant [26], and bfcko/srp double heterozygous embryos. The results showed that the Crq levels decreased to a similar extent in bfcko, srp mutant, and bfcko/srp double heterozygous embryos (Fig 5A, 5B and 5C). Furthermore, embryos carrying the double heterozygous combination of bfcko and srp (PI = 1.7 ± 0.15) exhibited similar defects to bfcko (PI = 1.67 ± 0.18) and srp (PI = 1.55 ± 0.13) in AC clearance (Fig 5D and 5E) as single homozygous mutants, while single heterozygous macrophages showed no clear phenotypic difference from that observed in wild type cells (PI = 3.27 ± 0.2) (S6E and S6F Fig). These results imply that Bfc acts together with Srp to upregulate Crq expression to promote an efficient efferocytosis.

Fig 5. Bfc interacts with Srp to regulate crq expression and efferocytosis.

Fig 5

A. The relative crq mRNA levels were quantified by qPCR in macrophages obtained from wild-type, homozygous bfcko or srp3, and double heterozygous bfcko and srp3 stage 13 embryos. B. Western blot analysis of the Crq protein levels in macrophages of wild-type, homozygous bfcko or srp3, and double heterozygous bfcko and srp3 stage 13 embryos. Actin was used as the loading control. C. Quantification of the Crq protein levels in (B) after normalization to the Actin levels; n = 3. D. Macrophages of wild-type, homozygous bfcko or srp3, and double heterozygous bfcko and srp3 stage 13 embryos were stained with anti-Crq (green) and anti-Dcp1 (magenta) antibodies. Scale bar = 20 μm. E. Graph showing the mean PIs ± SEM for each genotype in (D). F. The relative crq mRNA levels were quantified by qPCR in macrophages of wild-type, homozygous bfcko or crqko, and double heterozygous bfcko and crqko stage 13 embryos. G. Western blot analysis of the Crq protein levels in macrophages of wild-type, homozygous bfcko or crqko, and double heterozygous bfcko and crqko stage 13 embryos. Actin was used as the loading control. H. Quantification of the Crq protein levels in (G) after normalization to the Actin levels; n = 3. I. Macrophages of wild-type, homozygous bfcko or crqko, and double heterozygous bfcko and crqko stage 13 embryos were stained with anti-Crq (green) and anti-Dcp1 (magenta) antibodies. Scale bar = 20 μm. J. Graph showing the mean PIs ± SEM for each genotype in (I). Statistical significance was assessed using the one-way ANOVA.

As Srp is required for both the Crq expression and AC clearance, we speculated that bfc also affects the crq levels and efferocytosis in the same pathway. We generated a crqko mutant using CRISPR/Cas9 technique, and crossed it with the bfcko mutant to obtain crqko/bfcko double heterozygous mutants. qPCR and western blot analysis showed that the double heterozygous crqko/bfcko mutant embryos exhibited comparable decreased Crq levels as bfcko mutants, and phagocytic defects with reduced AC engulfment(PI = 1.32±0.15) as those observed in bfcko mutants (Fig 5F, 5G, 5H, 5I and 5J). Therefore, we hypothesized that Bfc serves as an Srp cofactor to promote the crq transcription and AC clearance during embryonic development.

Bfc enhances direct binding of GATA factor Srp to the crq promoter

The GATA factor Srp regulates the expression of Crq in embryonic macrophages [26]. To dissect how Bfc cooperates with Srp to regulate crq transcription, first, we identified the domains in Srp targeted by Bfc. We constructed truncated variants of Srp for Y2H and Co-IP assays (S7A Fig). These assays revealed that the zinc finger (ZnF) GATA domain of Srp is important for Bfc binding (S7B and S7C Fig). Notably, the ZnF GATA domain found in Srp has been described as a DNA-binding domain; the GATA factor was reported to have a C4 type zinc finger for binding to DNA (S7D Fig) [38]. Importantly, the mutant SrpZnF (Cys to Arg) showed impaired interaction between Srp and Bfc, indicating that Bfc interacts with a non-DNA binding region in the Srp ZnF domain (S7E Fig).

To detect the physical interactions between regulatory transcription factor proteins and crq at the genome level, we performed yeast one-hybrid (Y1H) assays [39] between Srp and the crq promoter locus. The results showed that Srp-AD interacted only with the crq promoter-3 (-401~800 bp upstream of crq) (Fig 6A and 6B). Importantly, sequencing analysis of the -1600 bp crq promoter element led to the discovery of one potential Srp-binding site [(A/T)GATA(A/G)], 494 bp upstream of crq, suggesting that Srp might regulate the transcription of crq via direct binding to its promoter. As expected, in the context of the mutant SrpZnF (from Cys to Arg), binding to the crq promoter was not detected (S7F Fig). To confirm that the GATA sequence in the crq promoter is required for crq expression, we mutated the GATA sequence in the Srp-binding site and integrated this construct, or the crqM-Gal4 construct (expression of Crq-Flag), as a control into the same genomic location. Our results showed that the ability of crqM-Gal4 to activate crq transcription was much weaker than that of crq-Gal4 (S8A, S8C, S8D and S8E Fig); of note, the deficiency in bfc also led to the insufficient activation of crq (S8A, S8B, S8D, S8E and S8F Fig). Moreover, we expressed the GFP protein drived by the mutated crq promoter to test its unspecific transcriptional activation, which showed crqM-Gal4 still had a relatively weak ability to activate UAS-GFP. Besides, the GFP signal in crqM-Gal4/ UAS-GFP; bfcko was as weak as that in the context of crqM-Gal4/ UAS-GFP (S9A, S9B and S9C Fig), which indicates that Bfc regulates crq transcription in a GATA-dependent manner. Moreover, ChIP qPCR assays showed that the amplification of the crq promoter region containing GATA in HA-Srp-transfected S2 cells (immunoprecipitated with anti-HA antibodies) was 25-fold higher than that obtained with control IgG antibodies (Fig 6C and 6D). Remarkably, the addition of ACs further increased the abundance of crq region co-immunoprecipitated with Srp (up to 40-fold versus the control IgG condition), supporting the idea that ACs induce the Srp-regulated transcription of crq. Furthermore, when we expressed Bfc in HA-Srp-transfected S2 cells, the crq region was significantly enriched (3-fold versus HA-Srp single-transfected S2 cells) (Fig 6C and 6D), while the overexpression of Bfc had no obvious influence on the Srp protein levels regardless of the presence of ACs (S9D and S9E Fig).

Fig 6. Srp binds to the GATA motif in the crq promoter.

Fig 6

A. Schematic representation of the crq promoter region; the red arrowhead indicates the predicted Srp binding site, and the black arrows indicate the primers used for the ChIP-qPCR. B. Yeast One-hybrid assays with yeast strains containing different prey (Srp-AD)—bait (crq promoter plasmids) combinations. C. The crosslinked chromatin of S2 cells expressing HA-Srp, HA-Srp+Bfc-Flag, or Bfc-Flag, incubated or not with ACs was immunoprecipitated with either anti-HA beads or control protein A/G. The ChIP-qPCR efficiency (compared to 5% input) is shown. Protein A/G was used as the negative control. D. The gel image shows the input DNA or immunoprecipitated DNA bands of the ChIP-qPCR in (C). E. Effect of bfc and srp RNAi treatments on the luciferase activity of crq promoter reporter constructs. All the samples were tested after the addition of ACs. The mean activity with the standard deviation of three independent transfections is represented. Statistical significance was assessed using the one-way ANOVA. F. Nuclear proteins extracted from HA-Srp transfected S2 cells binding to biotin-labeled crq promoter probe and EMSA supershift with and without anti-HA antibodies. The red arrows point to supershifted bands. F’. Purified GST-Srp protein binding to biotin-labeled crq probe and supershift with purified Bfc-6XHis.

To examine the requirement of Bfc and Srp for crq promoter activity during AC clearance, we conducted transient luciferase expression assays with the wild-type crq gene promoter-luciferase reporter gene; S2 cells were treated with bfc dsRNA or srp dsRNA after the addition of ACs. Knockdown of bfc or srp reduced the crq gene promoter activity by 39% and 50%, respectively (Fig 6E). On the other hand, Srp overexpression led to a 7.8-fold increase in the crq gene promoter activity; however, the knockdown of bfc in Srp-overexpressing S2 cells lowered the activity by 4.9-fold (Fig 6E). These results indicate that Bfc and Srp are required for crq promoter activity. To further investigate the role of Bfc in crq promoter activity, we performed electrophoretic mobility shift assay (EMSA) assays using Srp protein in vivo and in vitro. HA-Srp-transfected S2 nuclei formed a protein-DNA complex with biotin-labeled crq promoter DNA, whose migration was ‘shifted’ by the addition of anti-HA antibodies, indicating that Srp binds to the GATA sequence specifically (Fig 6F). Consistently, the addition of purified Bfc protein (1 μg) to the purified Srp-DNA complex also showed a super-shifted pattern compared to that of Srp-DNA alone (Fig 6F’, Lane 2). Of note, when we added increased amount of Bfc (2 μg and 4 μg) to the purified Srp-DNA complex, a more significant supershift was observed (Fig 6F’, Lane 3–4). As PI3K signaling and Stat92e reportedly activate the transcription of drpr [36], and Srp is required for the expression of Crq and Drpr [26], we further investigated whether Srp directly regulates the expression of phagocytic receptors. The Y1H results showed that only Srp, and neither Bfc nor Stat92e, bound directly to the crq promoter. However, we did not detect the binding of Srp to the drpr promoter (S10 Fig). Overall, these findings suggest that Srp directly binds to the crq promoter in conjunction with Bfc to regulate the Crq levels; thus, these proteins function together in regulating efferocytosis.

Discussion

In mammals, ACs are recognized by CD36, one of the several phagocyte cell surface receptors, with the AC surface molecules serving as cognate “eat-me” signals/ligands [40,41]. ACs also secrete molecules that attract distant phagocytes and modulate the immune response or phagocytic receptor activity. However, the mechanisms underlying this effect remain unclear. Crq is a CD36-related scavenger receptor in Drosophila and is expressed immediately after the onset of apoptosis in embryonic macrophages [8]. The expression of Crq is regulated by the extent of apoptosis, although the regulatory mechanisms by which ACs control the expression of Crq and subsequently induce phagocytosis in embryonic macrophages have not been described.

Here, we reveal a novel protein, Bfc (Booster for Crq), that plays a key role in efferocytosis via specifically regulating the expression of crq in a manner dependent on the extent of apoptosis. Bfc interacts with the zinc finger domain of the transcription factor Srp as a cofactor to enhance the binding of Srp to the crq promoter, leading to the upregulation of crq expression and the consequent induction of efferocytosis in Drosophila melanogaster. Importantly, our data reveal the molecular mechanisms by which ACs affect Crq expression, as well as how the phagocytic ability of embryonic macrophages is boosted in the presence of excessive apoptosis.

We found that in S2 cells, the ACs induced the transcriptional upregulation of crq (Fig 1A). In vivo, the macrophages developed as early as the first wave of developmentally programmed apoptosis began at embryogenic stage 11, when the expression of crq was activated and subsequently became widespread throughout the embryo (S3A, S3B, S3C and S3D Fig). Importantly, these results are similar to the regulatory mechanisms associated with the expression of other phagocytic receptors, such as Drpr and integrin [42,43]. For instance, studies showed that AC engulfment rapidly triggers an intracellular calcium burst followed by increased levels of drpr transcripts in Drosophila macrophages [16]; similarly, Draper and integrins become apically enriched soon after the engulfment of apoptotic debris in epithelial follicle cells [44].

We found that the expression of crq was elevated early after the co-culture of ACs and S2 cells, but gradually decreased to the basal levels as efferocytosis continued, suggesting that the regulation of AC clearance and crq expression follow a similar pattern. We demonstrated that most AC samples added to live S2 cells were composed of apoptotic cells rather than necrotic cells. However, we cannot eliminate the upregulated expression of genes in response to the presence of a few necrotic cells. Indeed, based on transcriptome analysis, we identified 12 genes that are required for AC clearance, which was confirmed by subsequent efferocytosis assays using their individual knockdown in S2 cells. Interestingly, among the 12 genes, two were related to innate immunity. CecA1, regulated at the transcriptional level encodes an antibacterial peptide [45], as well as a secreted protein that mediates the activation of the Toll pathway during bacterial infection [46]. This result may contradict the discreet nature of the apoptotic process [47,48]. However, ATPs released by bacteria are known to mediate inflammation [49], and the toll-like receptor 4 (TLR4) is activated by ACs to promote dendritic cell maturation and innate immunity in human monocyte-derived dendritic cells [50]. These results indicate that innate immune pathways are activated in the presence of ACs, and may contribute to their recognition or clearance in Drosophila.

Among these 12 genes, CG9129 (bfc) and CG30172 regulated the expression of crq and hence, efferocytosis. Further studies must be performed to elucidate the role of CG30172 in efferocytosis. On the other hand, we clearly dissected the role played by bfc in efferocytosis as well as the underlying mechanism. Using several different experimental approaches, we demonstrated that bfc regulates crq expression in response to excessive apoptosis. First, bfc RNAi treatment decreased the crq expression levels in S2 cells exposed to ACs, but not in the absence of ACs. Second, the increase in crq transcription was proportional to the extent of apoptosis in embryos, which was blocked by the loss of bfc. Notably, other phagocytic receptors have been reported to be activated by dying cells. The integrin heterodimer αPS3/βPS can be enriched in epithelial follicle cells after the engulfment of dying germline cells [42]. In addition, Drpr expression increases in follicle and glial cells, which activates the downstream JNK signaling during the clearance of apoptotic germline cells and neurons, respectively[35,43]. Collectively, the available scientific literature suggests that the expression of phagocytic receptors can be stimulated by the presence of excessive ACs to improve the phagocytic activity of macrophages or epithelial cells in different tissues.

Bioinformatics analysis of the conserved domains and gene structure indicated that Bfc does not likely function directly as a transcription factor. Here, we identified Srp as a Bfc interaction partner using yeast two-hybrid and Co-IP analyses. Shlyakhover et al. [26] reported that Srp is required for the expression of SIMU, Drpr, and Crq receptors in embryonic macrophages; however, our results demonstrated that bfc only affects the expression of crq expression through interaction with Srp, with no impact on the expression of several other genes. A plausible hypothesis for this phenotype is that Bfc assistance for Srp binding to the promoters of simu and drpr, may have limited effects. Thus, our results suggest that Bfc may regulate the Crq expression levels in the first wave of AC recognition via binding to Srp, whereas other regulatory factors participate in the Srp-mediated regulation of Drpr and SIMU.

We found that Srp directly binds to the DNA consensus sequence GATA [51] of the crq promoter via its highly conserved Cys-X2-Cys-X17-Cys-X2-Cys zinc finger binding domain (C4 motif) (Figs 6 and S7D). Meanwhile, Srp also interacts with Bfc through its zinc finger domain; curiously, while the mutation of the C4 motif did not affect the latter interaction, it completely blocked the former (S7 Fig). Importantly, we also showed that mutation in the GATA site abolished the expression of the crq in Drosophila embryo macrophages (S8 Fig). As a potential Srp cofactor, Bfc increased the ability of Srp to bind to the crq promoter, while bfc knockdown inhibited the crq transcriptional activity (Fig 6E and 6F). Ush (homolog of FOG-2 in Drosophila), a cofactor of GATA transcriptional factors [52], can bind Srp and limit crystal cell production during Drosophila blood cell development [53]. Interestingly, genetic studies have demonstrated that Ush acts with Srp to maintain the pluripotency of hemocyte progenitors and suppresses their differentiation [54,55]. Ush was reported to repress crq expression by interacting with the isoform of Srp, SrpNC(with two GATA zinc finger) while the other isoform of Srp, SrpC(with one GATA zinc finger) induced crq expression [25], which may indicate Bfc and Ush act on different isoforms of Srp to regulate crq expression by opposite mechanisms.

Although our results elucidate several factors that contribute to efferocytosis in Drosophila embryos, some mechanistic details remain unresolved; for instance, how ACs induce Bfc-mediated regulation of crq expression in macrophages remains unclear. We found that Bfc regulates Crq expression and efferocytosis, but not macrophage development (Fig 3E). Moreover, we found that Bfc-mediated activation of crq transcription and Crq accumulation leads to positive feedback to promote increased Bfc expression, which is required for engulfment (S2 Fig). As expected, the upregulation of Bfc expression occurred earlier than that of crq in S2 cells after incubation with ACs (S3F Fig). Therefore, further studies are required to elucidate the upstream signals in the context of the crq-mediated regulation of bfc expression. As previous studies have shown that Crq is required for phagosome maturation during the clearance of neuronal debris by epithelial cells and bacterial clearance [13,56], further studies should be conducted to determine whether Bfc is involved in the clearance of neuronal debris.

This study is not without limitations. For instance, other potential regulators of efferocytosis, whose expression is not affected by ACs could not be detected in our study. In mammals, CD36 is involved in the clearance of ACs [57] and regulates the host inflammatory response [58]. As a CD36 family homolog, Crq promotes the clearance of ACs and bacterial uptake via efferocytosis [56]. Researchers have reported that the GATA factor Srp is required for Crq expression [26]; here we confirmed this finding and showed that Srp directly binds to the crq promoter via its GATA binding site, which is enhanced by Bfc. However, no apparent Bfc homologs exist in vertebrates, and whether GATA factors regulate the CD36 family in a mechanism similar to that in flies remains unclear. Nevertheless, we predict that one or more functional homologs of Bfc may exist in mammals and are likely involved in apoptotic cell clearance. Unraveling them as well as determining whether and how bfc participates in eliminating pathogens and innate immunity is essential.

In summary, we showed that the expression of the engulfment receptor Crq is transcriptionally regulated by the presence of ACs, via Srp, and its newly identified cofactor, Bfc (Fig 7). Altogether, our findings imply that macrophages adopt a precise mechanism to increase the expression of engulfment receptors to boost their phagocytic activity, in the presence of excessive ACs. We anticipate a similar role and mechanism in the context of mammalian engulfment receptors in response to excessive ACs. Therefore, the findings of this study have significant implications for a wide range of human diseases, including those associated with aberrant apoptotic cell death and efferocytosis, such as tumor progression, neurodegenerative disorders, and other severe inflammatory conditions.

Fig 7. The AC-induced Crq expression is regulated by the Bfc-Srp pathway.

Fig 7

The basal Bfc expression remains at relatively low levels in the absence of ACs. However, in the presence of ACs, during efferocytosis, bfc expression is transcriptionally upregulated earlier than crq, and Bfc interacts with the GATA factor Srp to facilitate latter’s binding to the crq promoter. In turn, increased Crq levels likely enhance the ability of macrophages to engulf ACs and lead to the upregulated expression of Bfc via a positive feedback loop.

Materials and methods

Ethics statement

All experiments were performed in accordance with the approved guidelines. The animal experiments were performed in accordance with the Chinese Guidelines for the Care and Use of Laboratory Animals and approved by the Animal Care and Use Committee of the Shaanxi Normal University (Xi’an, China).

S2 cell culture and transfection

Drosophila S2 cells were cultured in Sf-900II SFM (Gibco) containing 50 units/ml penicillin and 50 μg/ml streptomycin at 25°C. Approximately 2×105 cells were plated 24 h before transfection; 2 μg DNA were transfected into S2 cells via DDAB-mediated transfection [59]. Transfected cells were harvested after 3 days.

Total RNA extraction and qPCR

Total RNA was extracted from S2 cells and flies using the TRIzol reagent (Invitrogen #15596026) and the Direct-zol RNA miniprep kit (Zymoresearch #R2052). RNA was reverse-transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche #04896866001), and qPCR was performed using the SYBR Mix (Roche # 04707516001) in an ABI Step One Plus instrument. Data represent the ratio or relative ratio of mRNA levels of the target gene (such as crq) to those of an internal reference gene (Rpl32). The qPCR primers used in this study are listed in S2 Table. All experiments were performed in triplicate with mRNA samples extracted from at least three biological replicates. Relative gene expression was quantified using the comparative method (ΔΔCT) [60,61].

Preparation of apoptotic cells and efferocytosis assays using S2 cells

S2 cells were treated with 0.25 μg/ml actinomycin D (Sigma) in culture medium for 18 h to induce apoptosis, washed three times with PBS, fixed with 8% paraformaldehyde for 10 min at room temperature (RT), and resuspended in SFM at a concentration of 107 cells/ml. For mRNA or protein expression analyses, apoptotic cells were directly added to live S2 cells at a ratio of 5:1. For the induction of efferocytosis in vitro, 1 ml ACs were labeled with 5 μg FITC-isomer suspension (Invitrogen #F-1906) for 1 h at RT in the dark. The cells were then washed twice with PBS, resuspended in 1 ml SFM, added to live S2 cells, and incubated for 6 h. Cells were counterstained with 10 μM CellTracker Blue CMAC Dye (Invitrogen #C2111) for 1 h, quenched with 0.4% trypan blue (Sigma), and observed under a confocal microscope (Nikon, C2). The acquired images were processed with the Adobe Photoshop CS6 and ImageJ software. As reported in previous studies [28,33], the ratio of double-labeled live cells (cell tracker blue and FITC-green) versus all live cells (cell tracker blue) was calculated to determine the percentage of efferocytosis.

RNA-seq assay

Total RNA of S2 cells was prepared as described above, and analyzed by the Annoroad Corporation. The libraries were constructed and sequenced using a HiSeq 2500 system (Illumina), which generated ~21 million read pairs per sample. Raw reads containing adapter, poly-N, and low-quality reads were filtered, and the effective data were mapped to the Drosophila melanogaster reference genome using TopHat (version 2.0.12)[62]. After excluding rRNA or tRNA sequences, we estimated the abundance of transcripts using fragments per kilobase per million mapped fragments (RPKM) [63]. The P values were adjusted using the Benjamini and Hochberg method [64]. Corrected P values < 0.05, and |log FC| ≥0.4, were set as the threshold for the significant difference in expression. The differentially expressed genes after filtering the RNA-seq data are denoted in the supplemental data.

All RNAseq data files are available from the NCBI SRA database (accession number PRJNA733098). The URLs is https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA733098.

All other data is available within the paper and its Supporting Information files.

Protein extraction and western blot analysis

Protein samples were lysed in 50 mM Tris-Cl [pH 7.4], 1% TritonX-100, 0.15 M NaCl, 1 mM EDTA with protease inhibitor. Lysates were centrifuged at 20,000 g for 30 min, and the supernatants were mixed with 5 × protein loading buffer for western blotting. For the embryo samples used for western blotting, we collected embryos laid on a 60 mm×60 mm yeasted apple juice agar plate, which were produced by 100–200 flies for 2 h at 25°C; the embryonic stages were determined according by Campos-Ortega and Hartenstein (1985).

The antibodies were used at the following dilutions: mouse anti-Crq (1:500), mouse anti-Bfc (1:500) (prepared in our lab), mouse anti-actin (CST), 1:1,000, mouse anti-Flag (Sigma) 1:1000, and mouse anti-HA (CST) 1:1000. Anti-rabbit or anti-mouse horseradish peroxidase (HRP)-coupled secondary antibodies (Jackson ImmunoResearch Laboratories) were used at a 1:10,000 dilution; ECL detection was performed following the supplier’s protocol (Pierce).

RNA interference treatment of S2 cells

Primers for the cloning of dsRNA were designed in Drosophila cell-based RNAi screen websites https://fgr.hms.harvard.edu/fly-cell-based-rnai; the T7 promoter sequence TAATACGACTCACTATAGGG was added to the 5′ end of each primer, and the High Yield RNA Synthesis Kit (NEB) was used for dsRNA synthesis using the corresponding PCR products as templates. The dsRNA primers used in this study are listed in S3 Table. For specific RNAi treatments, 500 μl S2 cells were treated with 5 μg dsRNA for 36 h and then FITC-labeled ACs were added and incubated at 25°C for 12 h to allow efficient efferocytosis. Subsequently, cells were collected for qPCR analysis and microscopic observation.

Fly strains and constructs

The following fly strains were used in this study: w1118, bfcMI02020 (#34268, Bloomington), srp3/TM3 (#2485, Bloomington), UAS-Bfc (Chr II, this study), UAS-GFP(#35786, Chr III, Bloomington), Crq-Gal4 (Chr II, this study), Crq proM-Gal4 (Chr II, this study), vasa Cas9 (#51323, Bloomington), bfc sgRNA (Chr II, this study), crq sgRNA(Chr III, this study), bfcko (bfc mutant obtained using CRISPR/Cas9, this study), and crqko (crq mutant obtained using CRISPR/Cas9, this study).

All flies were generated by Unihuaii Inc., unless otherwise specified. The crq-Gal4 and crq proM-Gal4 constructs were generated by PCR amplification of the 4000 bp fragment upstream of the crq gene (according to the reported crq-Gal4 sequence[65]) using the following primers: forward cctttcgtcttcaagaattcTGCGCCAGTTATCGACAGCT, reverse gggatcccggatctggtaccAATAGCCAAGGTGGGAATAATC; in the crq proM-Gal4 construct, GATA494 was mutated to CAGA494. The PCR product was directionally cloned into the Invitrogen pENTR/D-TOPO vector (Invitrogen #K240020), and then cloned into the pBGUw destination vector [15] using the Invitrogen Gateway LR Clonase Enzyme kit (Invitrogen #11791020). The construct was sequence verified, and transgenic flies were generated by Unihuaii Inc. using the PhiC31 targeted integration system.

The UAS-Bfc and UAS-CrqFlag constructs were constructed by PCR amplification of the genome using the following primers: Bfc forward caccATGAGAATGGACAAGTCGGA, Bfc reverse CTATGTCTTCTTGGCTGGCA; Crq forward caccATGTGCTGCAAGTGCTGCGG; Crq reverse CTACTTGTCATCGTCATCCTTGT. The same method was used to clone the PCR product into the pENTR/D-TOPO vector, followed by cloning in the pPWG destination vector. The construct was sequence verified, and transgenic flies were generated by Unihuaii Inc. using the P-element system. The bfc and crq sgRNA constructs were constructed using bfc and crq sgRNA oligos obtained from http://targetfinder.flycrispr.neuro.brown.edu/. The bfc and crq sgRNA constructs were generated using the following primers: Bfc sgRNA forward gtcgTCCTCCGGAGCGCAGAGGTT, Bfc sgRNA reverse aaacAACCTCTGCGCTCCGGAGGA; Crq sgRNA forward gtcgAACTTTATGCTGAACCATGA, Crq sgRNA reverse aaacTCATGGTTCAGCATAAAGTT. The constructs were verified by sequencing, and transgenic flies were generated by Unihuaii Inc. using the PhiC31 targeted integration system. The sgRNA transgenic flies were crossed with the vasa Cas9 strain to generate the Cas9-editing mutants, as verified by qPCR and sequencing.

Generation of anti-Bfc, -Crq and -Srp antibodies

The anti-Crq rabbit antibodies were a kind gift from Nathalie et al. [8]. Anti-Crq, anti-Bfc, and anti-Srp antibodies were raised via immunization of mice (BALB/c, 6–8-week-old), with the antigens including the amino acid positions 161–491, 1–250, and 911–1264, respectively; all recombinant proteins were fused to a 6×His tag and expressed in Escherichia coli. The recombinant DNA constructs used in this study are listed in S4 Table. All proteins were expressed in the form of inclusion bodies, resolved by SDS-PAGE, and stained with 0.25 M potassium chloride solution. The target protein bands were collected, and the proteins were dialyzed via horizontal electrophoresis, desalted, and concentrated to immunize the mice.

Immunostaining

Immunostaining was performed as described previously [26]. Briefly, stage 13 embryos were fixed and stained with different primary antibodies. Rabbit or mouse fluorescein-coupled and Cy5-coupled antibodies (Jackson Laboratories) were used as the secondary antibodies. The stained embryos were mounted in Vectashield medium (Vector Laboratories) and observed under a confocal microscope (Nikon, C2). The antibodies used in this study were rabbit anti-CRQ (1:400), mouse anti-Bfc (1:400), mouse anti-GFP (CST; 1:500), mouse anti-Flag (Sigma; 1:500), rabbit anti-HA (CST; 1:500), and rabbit anti-Dcp1 (CST, 1:500). The goat anti-rabbit Alexa Fluor Plus 594-coupled or anti-mouse Alexa Fluor Plus 488-coupled secondary antibodies (Jackson ImmunoResearch Laboratories) were used at a 1:1000 dilution.

Acridine Orange staining of Drosophila embryos

The AO staining was performed as described previously [66]. Briefly, embryos were collected at stage 13 and dechorionated in fresh 50% bleach until the dorsal appendages were no longer visible. The embryos were then washed with distilled H2O to remove the bleach and transferred into 1 ml heptane and 1 ml 2.5 μg/ml AO (Molecular Probes) in 0.1 M phosphate buffer, pH 7. Remove the embryos from the interface and dropped them onto a glass slide, and followed by placing the coverslip. Staining was observed in FITC channels.

Determination of the phagocytic index (PI)

PI was calculated as the average number of apoptotic particles in each macrophage [33]. In general, five embryos per genotype and four parts (head, dorsal side, ventral side, and tail) of each embryo were acquired as confocal image stacks; only the head pictures are shown [8,15,66]. Confocal imaging was performed on a Nikon C2 confocal microscope. The standard error of the mean (SEM) was obtained from the calculated PIs.

Yeast two-hybrid assay

Each relevant gene was cloned into the pGADT7 or pGBDT7 plasmid (Clontech). The plasmids were transformed into AH109 yeast strain in pairs. The transformed yeast was cultured on SD–Trp/-Leu double-dropout solid culture medium. After PCR testing, individual positive yeast colonies were picked into a new culture medium and incubated overnight. Colonies were then diluted to 10−1, 10−2 and 10−3 cfu, and added into SD–Trp/-Leu/-His triple dropout solid culture medium. Images of yeast cultures were obtained after 3 d culture at 30°C.

Co-Immunoprecipitation (Co-IP)

Plasmids encoding the differently expressed tagged proteins were co-transfected into S2 cells as previously described; immunoprecipitation was carried out at 4°C. Briefly, transfected S2 cells were lysed in 50 mM Tris-Cl [pH 7.4], 1% TritonX-100, 0.15 M NaCl, 1 mM EDTA with protease inhibitor followed by centrifugation. The supernatants were incubated with anti-Flag M2 magnetic beads (Sigma#M8823) for 2 h at 4°C. The beads were washed three times with TBS (50 mM Tris, 150 mM NaCl), boiled in 2×SDS loading buffer for 5 min, the supernatants were detected by western blotting.

Yeast one-hybrid assay

The DNA bait sequence was cloned into the pAbAi vector, for the subsequent integration of the pBait-AbAi plasmid into the Y1HGold yeast genome and the creation of a bait/reporter strain. The background AbA’ expression of the Y1HGold bait strain was tested by plating 10 μl yeast on SD/-Ura media supplemented with Aureobasidin A(AbAi) (100–1000 ng/ml); the minimal concentration of AbA, or a concentration that was slightly higher than the one that completely suppresses the growth of the bait strain was used for the screening interacting proteins. The cDNA of indicated transcriptional factor was cloned into pGADT7, transformed into the Y1HGold bait strain, and 10 μl of 10−1, 10−2 and 10−3 dilutions were spotted onto selective medium containing 300 ng/ml ABA and no histidine (-His), followed by 3 d incubation at 30°C. Positive and negative controls were included for all experiments.

ChIP assay

10×cell lysis buffer (50 mM HEPES, 50 mM NaCl, 10 mM EDTA, 5 mM EGTA), and Triton X-100 were directly added to a final concentration 1× and 0.5%, respectively to 5×107 exponentially growing cells in 10 ml growth media. The protein-DNA bonds were cross-linked by the addition of 1% formaldehyde, and cross-linking was stopped by adding and incubating 100 mM glycine for 15 min. After centrifugation, the cell pellet was suspended in 200 μl sonic buffer (10 mM Tris pH 8.0, 1 mM EDTA, 0.5 mM EGTA), and sonicated (on ice) to break the DNA into fragments. The lysates were centrifuged for 10 min at 16,000 × g, the supernatant was diluted in 800 μL dilution buffer (10 mM Tris, pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl), and incubated with HA magnetic beads (Pierce # 88836) or protein A/G magnetic beads (Pierce # 88802) overnight at 4°C on a rotating device. The beads were washed five times with dilution buffer. After the last wash, 50 μL elution buffer (1% SDS, 100 mM NaHCO3) was added to elute the immunoprecipitated DNA. The protein-DNA crosslinks were reversed by heating at 65°C for 4 h. After deproteinization with proteinase K, DNA was recovered by phenol-chloroform extraction and ethanol precipitation. Finally, 2–10 μL of the DNA per sample was subjected to qPCR.

Luciferase reporter assays

Approximately 2 ×105 S2 cells were plated in 24-well dishes 24 h before plasmid transfection; 500 ng pGL3-crqPro plasmid and 1 ng pAct5C-seapanzy as an internal control were co-transfected into cells using DDAB-mediated transfection. After 48 h, S2 cells were harvested, and the luciferase activity was determined according to the manufacturer’s instructions (Promega#E1960). Normalization to the Renilla luciferase activity was performed. Transfections were performed three times independently. For target gene-RNAi experiments, 5 μg/well dsRNA was added 24 h before plasmid transfection.

Electrophoretic mobility shift assay

The EMSA has been used extensively to study DNA-protein interactions [67]. Biotin 5’ end-labeled DNA targets were prepared and the assay was performed using the LightShift Chemiluminescent EMSA Kit (Thermo#20148), as per the manufacturer’s instructions. Biotin–EBNA Control DNA, Unlabeled EBNA DNA, and Epstein-Barr nuclear antigen (EBNA) extract were used as controls.

The biotin-labeled crq promoter DNA containing the binding site was annealed by PCR to form oligos using the following primers: crq forward GGACGCGTACGGTTTTGATAGTTCCGATTGTG, and reverse CACAATCGGAACTATCAAAACCGTACGCGTCC. The biotin–unlabeled crq promoter DNA containing the binding site was annealed by PCR to form oligos using the following primers: crq forward CGTACGGTTTTGATAGTTCCG and reverse CGGAACTATCAAAACCGTACG.

Using 2 μL nuclear extract per 20 μL binding reaction, nuclear proteins from the HA-Srp-transfected S2 cells were extracted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo #78833). Anti-HA (rabbit, CST, 1 μL per reaction) was used to observe the supershift of anti-HA/HA-Srp/DNA. Srp-GST and Bfc-His were expressed and purified as previously described [68]. The Bfc pET28a construct was constructed by PCR amplification using the following primers: Bfc-his forward tggacagcaaatgggtcgcATGAGAATGGACAAGTCGGA, Bfc-his reverse tggtggtggtggtggtgTGTCTTCTTGGCTGGCACG. The Srp pGEX KG construct was constructed by PCR amplification using the following primers: Srp-GST forward ggtggtggtggaattcATGACGAAAACGACAAAGCC and Srp-GST reverse tcacgatgaattaagcttCTCCATCTTCACCACTG.

Statistical analysis

Statistical P-values were determined using the one- or two-way analysis of the variance or the Student’s t-test. “*” indicates P< 0.05; “**” indicates P<0.01; “***” indicates P<0.001, “****” indicates P<0.0001. The error bars represent the SEM.

Supporting information

S1 Fig. ACs were successfully generated from S2 cells, and the RNAi knockdown efficiency was confirmed by qPCR.

A. S2 cells and ACs were stained with annexin V-FITC and propidium iodide (PI). Scale bar = 20 μm. ACs were obtained from S2 cells after Actinomycin D induction for 18 h, as described in the Materials and Methods section. B. The apoptosis rates of S2 cells and ACs were analyzed by flow cytometry. C. Western blotting detected the Dcp1 protein levels in S2 cells and ACs. Actin was used as the loading control. D. The relative mRNA levels of 24 genes in RNAi-treated S2 cell lines were quantified by qPCR and compared to those of control-treated S2 cells; RpL32 was used as the internal control. Statistical significance was assessed using the two-way ANOVA.

(TIF)

S2 Fig. CG9129 and crq regulate each other at the transcriptional level during the clearance of ACs in S2 cells.

A. The CG9129 mRNA levels were quantified by qPCR in Crq-overexpressing S2 cells (Crq-GFP) and control S2 cells. The crq mRNA levels were also quantified by qPCR in CG9129 over-expressing S2 cells (CG9129-flag) and control S2 cells. 0 h refers to S2 cells in the absence of ACs; 6 h refers to S2 cells co-incubated with ACs for 6 h. RpL32 was used as the internal control. B. The CG9129 mRNA levels were also determined in RNAi-treated S2 cells (control and for the knockdown of crq) after co-incubation with ACs for 6 h, by qPCR. Statistical significance was assessed using the two-way ANOVA (A) or Student’s t-test (B).

(TIF)

S3 Fig. Bfc regulates the expression of Crq in vivo.

A. The relative crq mRNA levels in stage 7–14 wild type embryos were quantified by qPCR; significant differences were observed compared to the expression in stage 7 embryos. B. The bfc mRNA levels in stage 7–14 wild-type embryos were quantified by qPCR; significant differences were observed compared to the expression in stage 7 embryos. C. The relative crq mRNA levels were quantified and compared in the same stage of wild type and bfcko mutant embryos by qPCR. D. Western blot analysis was used for the detection of the Crq protein levels in stage 11–14 embryos of wild type and bfc mutant flies. Actin was used as the loading control. E. The relative Crq protein levels in stage 11–14 wild type, and bfcko mutant embryos were analyzed via western blotting. The protein levels were normalized to those of actin. Significant differences were observed in comparison with stage 11 wild-type embryos; n = 3. F. The relative crq and bfc mRNA levels were quantified by qPCR in stage to 10–13 wild-type w1118 and H99 (absence of apoptosis) embryos. G. The crq, bfc, and drpr mRNA levels were quantified by qPCR and normalized to the Rpl32 mRNA levels. “*”/“#”/“※” represent the significant differences in the context of crq/bfc/drpr expression, respectively. “##” indicates P<0.01; “###” indicates P<0.001; “####” indicates P<0.0001; “※※” indicates P<0.01. H. The drpr mRNA levels were quantified by qPCR in wild-type S2 cells and bfc-RNAi S2 cells in the presence or absence of ACs. Statistical significance was assessed using the one-way ANOVA(A, B, E, F, H) or two-way ANOVA (C, G).

(TIF)

S4 Fig. bfc knockout reduced crq expression without affecting macrophage development in the embryos.

A. The crq, drpr, and simu mRNA levels were quantified by qPCR in stage 13 wild-type, bfcko, and srp mutant embryos. B. Macrophages were stained with anti-CRQ (green) antibodies, and ACs were stained with anti-Dcp1 (magenta) antibodies in stage 13 wild-type and bfcko embryos. Scale bar = 20 μm. C. Graph showing the number of macrophages ± SEM for genotype of wild type, bfcko, srp-Gal4>UAS-GFP and bfcko; srp-Gal4>UAS-GFP. Statistical significance was assessed using the two-way ANOVA (A) or one-way ANOVA (C).

(TIF)

S5 Fig. Bfc is required for efferocytosis of embryonic macrophages.

A. Z-stack of eight images from a single macrophage of wild type and bfcko embryos taken at intervals of 1 μm. Scale bar = 5 μm. B-B’. Control srp-Gal4>UAS-GFP embryo macrophages were labeled with srp-Gal4>UAS-GFP (green); anti-Dcp1 was labeled in magenta. C-C’. bfcko; srp-Gal4>UAS-GFP embryo macrophages were labeled as srp-Gal4>UAS-GFP (green); anti-Dcp1 was labeled in magenta. Scale bar = 20 μm. D. Graph showing the mean PIs ± SEM for each genotype (A-C). Statistical significance was assessed using the one-way ANOVA.

(TIF)

S6 Fig. bfcMI02020 mutants show a defective efferocytosis of ACs.

A. The crq and bfc mRNA levels were quantified by qPCR using wild-type and bfcMI02020 embryos. B. Graph showing the mean PI ± SEM for each genotype in (C). C. Anti-CRQ (green) and anti-Dcp1 (magenta) antibodies were used to stain the apoptotic bodies in macrophages of stage 13 wild-type, bfcMI02020, and bfcMI02020 re-expressing UAS-bfc (under the control of a crq-Gal4 driver) embryos. The white arrowheads point to non-engulfed ACs. Scale bar = 20 μm. D. Anti-CRQ (green) and anti-Dcp1 (magenta) antibodies were used to stain the apoptotic bodies in macrophages of stage 13 wild-type, bfcko, and bfcko re-expressing UAS-crq (under the control of a crq-Gal4 driver) embryos. The white arrowheads point to non-engulfed ACs. Scale bar = 20 μm. E. Graph showing the mean PI ± SEM for each genotype in (D). F. Anti-CRQ (green) and anti-Dcp1 (magenta) antibodies were used to stain the apoptotic bodies in heterozygous macrophages of stage 13 bfcko/+ and srp/+ embryos. The white triangles point to non-engulfed ACs. Scale bar = 20 μm. Statistical significance was assessed using the two-way ANOVA (A) or one-way ANOVA (B, E).

(TIF)

S7 Fig. bfc and the crq promoter interact with the ZnF GATA domain of Srp.

A. Schematic diagram showing the domains of Srp and the truncations generated to examine the potential Bfc-Srp interactions. B and C. The interaction between Bfc and Srp was examined using the yeast two-hybrid (B) and Co-IP assays (C). D. Schematic diagram showing the C4M mutants with the substitution of eight cysteines by arginines in the C4 motif of Srp. E. The yeast two-hybrid assay showing the interaction between Bfc and the C4M Srp mutant. F. The yeast one-hybrid assay shows the lack of interaction between the crq promoter C4M and the C4M Srp mutant.

(TIF)

S8 Fig. Mutations in the GATA site result in the weaker activation of Crq expression in Drosophila embryos.

A. Anti-Flag (green) and anti-Dcp1 (magenta) antibodies were used to stain macrophages and ACs of stage 13 wild-type, bfc mutant re-expressing UAS-CrqFlag (under the control of a crq-Gal4 driver), and wild-type re-expressing UAS-CrqFlag (driven by mutated crq-Gal4) embryos. Scale bar = 20 μm. B and C. The Flag protein levels were determined via western blotting for each genotype in (A). Actin was used as the loading control. D. Quantification of the Flag protein levels in (B) and (C) after normalization to those of actin (n = 3). E. The Crq protein levels were detected via western blotting in the context of w1118, bfcko, bfcko mutant re-expressing UAS-CrqFlag (driven by crq-Gal4), and wild-type re-expressing UAS-CrqFlag (driven by crq-Gal4) samples. Actin was used as the loading control. F. Quantification of the Crq protein levels in (E) after normalization to those of actin (n = 3). Statistical significance was assessed using the Student’s t-test.

(TIF)

S9 Fig. Bfc activates crq promoter to drive GFP protein through the GATA site in Drosophila embryos, while Bfc has no influence on Srp level.

A-A”. Anti-GFP (green) and anti-Dcp1 (Red) antibodies were used to stain macrophages and ACs of stage 13 embryos in crq-Gal4>UAS-GFP(A), crqM-Gal4>UAS-GFP(A’), and crqM-Gal4>UAS-GFP; bfcko(A”). Scale bar = 20 μm. B. The GFP protein levels were determined via western blotting using crq-Gal4>UAS-GFP, crqM-Gal4>UAS-GFP, and crqM-Gal4>UAS-GFP; bfcko embryos. Actin was used as the loading control. C. Quantification of the protein levels in (B) after normalization to actin; n = 3. Statistical significance was assessed using the Student’s t-test. D. The Crq and Srp protein levels were determined via western blot analysis in blank, Bfc-overexpressing, and bfc-RNAi-treated S2 cells in the presence or absence of ACs. Actin was used as the loading control. E. Quantification of the protein levels in (D) after normalization to actin; n = 3. Statistical significance was assessed using the one-way ANOVA(C) and two-way ANOVA(E).

(TIF)

S10 Fig. The yeast one-hybrid assay revealed that Srp and Stat92e bind to the crq promoter and drpr promoter, respectively.

A. Schematic diagram showing the domain of the crq promoter used for the yeast one-hybrid assay. B. The yeast one-hybrid assay shows the interactions between Srp-AD, Bfc-AD, Stat92e-AD, and the crq promoter. C. Schematic diagram showing the domain of the drpr promoter used for the yeast one-hybrid assay. D. The yeast one-hybrid shows the interactions between Srp-AD, Bfc-AD, Stat92e-AD, and the drpr promoter.

(TIF)

S1 Data. Differentially expressed genes from comparisons of 6h versus 0h, 12h versus 0h, and 6h versus 12 h, respectively.

(XLSX)

S1 Table. RNA-seq data of the 50 filtered genes.

Representative genes were selected across a range of expression levels.

(DOCX)

S2 Table. qPCR primers used to obtain the data represented in Fig 2.

(DOCX)

S3 Table. dsRNA primers used to obtain the data represented Fig 2.

(DOCX)

S4 Table. Recombinant DNA constructs used in this study.

(DOCX)

S5 Table. Raw data for the statistical graphs used in all figures.

(XLSX)

Acknowledgments

We thank the Bloomington Drosophila Stock Center for the Drosophila melanogaster strains. We would like to thank Editage (www.editage.cn) for English language editing.

Data Availability

All RNAseq data files are available from the NCBI SRA database (accession number PRJNA733098). The URLs is https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA733098 All other data is available within the paper and its Supporting Information files.

Funding Statement

H.X. received grants 91954114 and 31671439 from the National Natural Science Foundation of China (http://www.nsfc.gov.cn).Q.Z. received grant 31801164 from the National Natural Science Foundation of China (http://www.nsfc.gov.cn). H.X. received grants GK202001004 and GK202007009 from Shaanxi Normal University (http://www.snnu.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.deCathelineau AM, Henson PM. The final step in programmed cell death: phagocytes carry apoptotic cells to the grave. Essays Biochem. 2003;39:105–17. doi: 10.1042/bse0390105 [DOI] [PubMed] [Google Scholar]
  • 2.Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006;27(5):244–50. doi: 10.1016/j.it.2006.03.005 [DOI] [PubMed] [Google Scholar]
  • 3.Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annual review of immunology. 1999;17:593–623. doi: 10.1146/annurev.immunol.17.1.593 [DOI] [PubMed] [Google Scholar]
  • 4.Franc NC, White K, Ezekowitz RA. Phagocytosis and development: back to the future. Current opinion in immunology. 1999;11(1):47–52. doi: 10.1016/s0952-7915(99)80009-0 [DOI] [PubMed] [Google Scholar]
  • 5.Nagata S. Apoptosis and autoimmune diseases. IUBMB life. 2006;58(5–6):358–62. doi: 10.1080/15216540600746401 [DOI] [PubMed] [Google Scholar]
  • 6.Zheng Q, Ma A, Yuan L, Gao N, Feng Q, Franc NC, et al. Apoptotic Cell Clearance in Drosophila melanogaster. Front Immunol. 2017;8:1881. doi: 10.3389/fimmu.2017.01881 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Serizier SB, McCall K. Scrambled Eggs: Apoptotic Cell Clearance by Non-Professional Phagocytes in the Drosophila Ovary. Front Immunol. 2017;8:1642. doi: 10.3389/fimmu.2017.01642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Franc NC, Heitzler P, Ezekowitz RA, White K. Requirement for croquemort in phagocytosis of apoptotic cells in Drosophila. Science. 1999;284(5422):1991–4. doi: 10.1126/science.284.5422.1991 [DOI] [PubMed] [Google Scholar]
  • 9.Manaka J, Kuraishi T, Shiratsuchi A, Nakai Y, Higashida H, Henson P, et al. Draper-mediated and phosphatidylserine-independent phagocytosis of apoptotic cells by Drosophila hemocytes/macrophages. J Biol Chem. 2004;279(46):48466–76. doi: 10.1074/jbc.M408597200 [DOI] [PubMed] [Google Scholar]
  • 10.Kurant E, Axelrod S, Leaman D, Gaul U. Six-microns-under acts upstream of Draper in the glial phagocytosis of apoptotic neurons. Cell. 2008;133(3):498–509. doi: 10.1016/j.cell.2008.02.052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Fullard JF, Kale A, Baker NE. Clearance of apoptotic corpses. Apoptosis. 2009;14(8):1029–37. doi: 10.1007/s10495-009-0335-9 [DOI] [PubMed] [Google Scholar]
  • 12.Xiao H, Wang H, Silva EA, Thompson J, Guillou A, Yates JR Jr., et al. The Pallbearer E3 ligase promotes actin remodeling via RAC in efferocytosis by degrading the ribosomal protein S6. Dev Cell. 2015;32(1):19–30. doi: 10.1016/j.devcel.2014.11.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Han C, Song Y, Xiao H, Wang D, Franc NC, Jan LY, et al. Epidermal cells are the primary phagocytes in the fragmentation and clearance of degenerating dendrites in Drosophila. Neuron. 2014;81(3):544–60. doi: 10.1016/j.neuron.2013.11.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Crozatier M, Meister M. Drosophila haematopoiesis. Cell Microbiol. 2007;9(5):1117–26. doi: 10.1111/j.1462-5822.2007.00930.x [DOI] [PubMed] [Google Scholar]
  • 15.Franc NC, Dimarcq JL, Lagueux M, Hoffmann J, Ezekowitz RA. Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. Immunity. 1996;4(5):431–43. doi: 10.1016/s1074-7613(00)80410-0 [DOI] [PubMed] [Google Scholar]
  • 16.Weavers H, Evans IR, Martin P, Wood W. Corpse Engulfment Generates a Molecular Memory that Primes the Macrophage Inflammatory Response. Cell. 2016;165(7):1658–71. doi: 10.1016/j.cell.2016.04.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ohsawa S, Sugimura K, Takino K, Xu T, Miyawaki A, Igaki T. Elimination of oncogenic neighbors by JNK-mediated engulfment in Drosophila. Dev Cell. 2011;20(3):315–28. doi: 10.1016/j.devcel.2011.02.007 [DOI] [PubMed] [Google Scholar]
  • 18.MacDonald JM, Beach MG, Porpiglia E, Sheehan AE, Watts RJ, Freeman MR. The Drosophila cell corpse engulfment receptor Draper mediates glial clearance of severed axons. Neuron. 2006;50(6):869–81. doi: 10.1016/j.neuron.2006.04.028 [DOI] [PubMed] [Google Scholar]
  • 19.Awasaki T, Tatsumi R, Takahashi K, Arai K, Nakanishi Y, Ueda R, et al. Essential role of the apoptotic cell engulfment genes draper and ced-6 in programmed axon pruning during Drosophila metamorphosis. Neuron. 2006;50(6):855–67. doi: 10.1016/j.neuron.2006.04.027 [DOI] [PubMed] [Google Scholar]
  • 20.Ziegenfuss JS, Biswas R, Avery MA, Hong K, Sheehan AE, Yeung YG, et al. Draper-dependent glial phagocytic activity is mediated by Src and Syk family kinase signalling. Nature. 2008;453(7197):935–9. doi: 10.1038/nature06901 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nonaka S, Nagaosa K, Mori T, Shiratsuchi A, Nakanishi Y. Integrin alphaPS3/betanu-mediated phagocytosis of apoptotic cells and bacteria in Drosophila. J Biol Chem. 2013;288(15):10374–80. doi: 10.1074/jbc.M113.451427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kocks C, Cho JH, Nehme N, Ulvila J, Pearson AM, Meister M, et al. Eater, a transmembrane protein mediating phagocytosis of bacterial pathogens in Drosophila. Cell. 2005;123(2):335–46. doi: 10.1016/j.cell.2005.08.034 [DOI] [PubMed] [Google Scholar]
  • 23.Roddie HG, Armitage EL, Coates JA, Johnston SA, Evans IR. Simu-dependent clearance of dying cells regulates macrophage function and inflammation resolution. PLoS Biol. 2019;17(5):e2006741. doi: 10.1371/journal.pbio.2006741 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Rehorn KP, Thelen H, Michelson AM, Reuter R. A molecular aspect of hematopoiesis and endoderm development common to vertebrates and Drosophila. Development. 1996;122(12):4023–31. [DOI] [PubMed] [Google Scholar]
  • 25.Waltzer L, Bataille L, Peyrefitte S, Haenlin M. Two isoforms of Serpent containing either one or two GATA zinc fingers have different roles in Drosophila haematopoiesis. EMBO J. 2002;21(20):5477–86. doi: 10.1093/emboj/cdf545 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Shlyakhover E, Shklyar B, Hakim-Mishnaevski K, Levy-Adam F, Kurant E. Drosophila GATA Factor Serpent Establishes Phagocytic Ability of Embryonic Macrophages. Front Immunol. 2018;9:266. doi: 10.3389/fimmu.2018.00266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Schneider I. Cell lines derived from late embryonic stages of Drosophila melanogaster. J Embryol Exp Morphol. 1972;27(2):353–65. [PubMed] [Google Scholar]
  • 28.Silva EA, Burden J, Franc NC. In vivo and in vitro methods for studying apoptotic cell engulfment in Drosophila. Methods Enzymol. 2008;446:39–59. doi: 10.1016/S0076-6879(08)01603-0 [DOI] [PubMed] [Google Scholar]
  • 29.Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078–9. doi: 10.1093/bioinformatics/btp352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Okada R, Nagaosa K, Kuraishi T, Nakayama H, Yamamoto N, Nakagawa Y, et al. Apoptosis-dependent externalization and involvement in apoptotic cell clearance of DmCaBP1, an endoplasmic reticulum protein of Drosophila. J Biol Chem. 2012;287(5):3138–46. doi: 10.1074/jbc.M111.277921 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Vieira FG, Rozas J. Comparative genomics of the odorant-binding and chemosensory protein gene families across the Arthropoda: origin and evolutionary history of the chemosensory system. Genome Biol Evol. 2011;3:476–90. doi: 10.1093/gbe/evr033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tepass U, Fessler LI, Aziz A, Hartenstein V. Embryonic origin of hemocytes and their relationship to cell death in Drosophila. Development. 1994;120(7):1829–37. [DOI] [PubMed] [Google Scholar]
  • 33.Cuttell L, Vaughan A, Silva E, Escaron CJ, Lavine M, Van Goethem E, et al. Undertaker, a Drosophila Junctophilin, links Draper-mediated phagocytosis and calcium homeostasis. Cell. 2008;135(3):524–34. doi: 10.1016/j.cell.2008.08.033 [DOI] [PubMed] [Google Scholar]
  • 34.Venken KJ, Schulze KL, Haelterman NA, Pan H, He Y, Evans-Holm M, et al. MiMIC: a highly versatile transposon insertion resource for engineering Drosophila melanogaster genes. Nat Methods. 2011;8(9):737–43. doi: 10.1038/nmeth.1662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Etchegaray JI, Timmons AK, Klein AP, Pritchett TL, Welch E, Meehan TL, et al. Draper acts through the JNK pathway to control synchronous engulfment of dying germline cells by follicular epithelial cells. Development. 2012;139(21):4029–39. doi: 10.1242/dev.082776 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Doherty J, Sheehan AE, Bradshaw R, Fox AN, Lu TY, Freeman MR. PI3K signaling and Stat92E converge to modulate glial responsiveness to axonal injury. PLoS Biol. 2014;12(11):e1001985. doi: 10.1371/journal.pbio.1001985 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Musashe DT, Purice MD, Speese SD, Doherty J, Logan MA. Insulin-like Signaling Promotes Glial Phagocytic Clearance of Degenerating Axons through Regulation of Draper. Cell Rep. 2016;16(7):1838–50. doi: 10.1016/j.celrep.2016.07.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Wang T, Yang Y, Lou S, Wei W, Zhao Z, Ren Y, et al. Genome-Wide Characterization and Gene Expression Analyses of GATA Transcription Factors in Moso Bamboo (Phyllostachys edulis). Int J Mol Sci. 2019;21(1). doi: 10.3390/ijms21010014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Reece-Hoyes JS, Marian Walhout AJ. Yeast one-hybrid assays: a historical and technical perspective. Methods. 2012;57(4):441–7. doi: 10.1016/j.ymeth.2012.07.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Fadok VA, Warner ML, Bratton DL, Henson PM. CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v beta 3). J Immunol. 1998;161(11):6250–7. [PubMed] [Google Scholar]
  • 41.Miksa M, Amin D, Wu R, Ravikumar TS, Wang P. Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages. Mol Med. 2007;13(11–12):553–60. doi: 10.2119/2007-00019.Miksa [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Meehan TL, Kleinsorge SE, Timmons AK, Taylor JD, McCall K. Polarization of the epithelial layer and apical localization of integrins are required for engulfment of apoptotic cells in the Drosophila ovary. Dis Model Mech. 2015;8(12):1603–14. doi: 10.1242/dmm.021998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hilu-Dadia R, Hakim-Mishnaevski K, Levy-Adam F, Kurant E. Draper-mediated JNK signaling is required for glial phagocytosis of apoptotic neurons during Drosophila metamorphosis. Glia. 2018;66(7):1520–32. doi: 10.1002/glia.23322 [DOI] [PubMed] [Google Scholar]
  • 44.Peterson JS, Timmons AK, Mondragon AA, McCall K. The End of the Beginning: Cell Death in the Germline. Curr Top Dev Biol. 2015;114:93–119. doi: 10.1016/bs.ctdb.2015.07.025 [DOI] [PubMed] [Google Scholar]
  • 45.Kylsten P, Samakovlis C, Hultmark D. The cecropin locus in Drosophila; a compact gene cluster involved in the response to infection. EMBO J. 1990;9(1):217–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Wang L, Weber AN, Atilano ML, Filipe SR, Gay NJ, Ligoxygakis P. Sensing of Gram-positive bacteria in Drosophila: GNBP1 is needed to process and present peptidoglycan to PGRP-SA. EMBO J. 2006;25(20):5005–14. doi: 10.1038/sj.emboj.7601363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Trahtemberg U, Mevorach D. Apoptotic Cells Induced Signaling for Immune Homeostasis in Macrophages and Dendritic Cells. Front Immunol. 2017;8:1356. doi: 10.3389/fimmu.2017.01356 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Yamaguchi H, Maruyama T, Urade Y, Nagata S. Immunosuppression via adenosine receptor activation by adenosine monophosphate released from apoptotic cells. Elife. 2014;3:e02172. doi: 10.7554/eLife.02172 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Trautmann A. Extracellular ATP in the immune system: more than just a "danger signal". Sci Signal. 2009;2(56):pe6. doi: 10.1126/scisignal.256pe6 [DOI] [PubMed] [Google Scholar]
  • 50.Pathak SK, Skold AE, Mohanram V, Persson C, Johansson U, Spetz AL. Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and beta2 integrins. J Biol Chem. 2012;287(17):13731–42. doi: 10.1074/jbc.M111.336545 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhang Z, Zou X, Huang Z, Fan S, Qun G, Liu A, et al. Genome-wide identification and analysis of the evolution and expression patterns of the GATA transcription factors in three species of Gossypium genus. Gene. 2019;680:72–83. doi: 10.1016/j.gene.2018.09.039 [DOI] [PubMed] [Google Scholar]
  • 52.Cubadda Y, Heitzler P, Ray RP, Bourouis M, Ramain P, Gelbart W, et al. u-shaped encodes a zinc finger protein that regulates the proneural genes achaete and scute during the formation of bristles in Drosophila. Genes Dev. 1997;11(22):3083–95. doi: 10.1101/gad.11.22.3083 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Muratoglu S, Hough B, Mon ST, Fossett N. The GATA factor Serpent cross-regulates lozenge and u-shaped expression during Drosophila blood cell development. Dev Biol. 2007;311(2):636–49. doi: 10.1016/j.ydbio.2007.08.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lenz J, Liefke R, Funk J, Shoup S, Nist A, Stiewe T, et al. Ush regulates hemocyte-specific gene expression, fatty acid metabolism and cell cycle progression and cooperates with dNuRD to orchestrate hematopoiesis. PLoS Genet. 2021;17(2):e1009318. doi: 10.1371/journal.pgen.1009318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Tokusumi Y, Tokusumi T, Stoller-Conrad J, Schulz RA. Serpent, suppressor of hairless and U-shaped are crucial regulators of hedgehog niche expression and prohemocyte maintenance during Drosophila larval hematopoiesis. Development. 2010;137(21):3561–8. doi: 10.1242/dev.053728 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Guillou A, Troha K, Wang H, Franc NC, Buchon N. The Drosophila CD36 Homologue croquemort Is Required to Maintain Immune and Gut Homeostasis during Development and Aging. PLoS Pathog. 2016;12(10):e1005961. doi: 10.1371/journal.ppat.1005961 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Hopkinson-Woolley J, Hughes D, Gordon S, Martin P. Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse. J Cell Sci. 1994;107 (Pt 5):1159–67. [DOI] [PubMed] [Google Scholar]
  • 58.Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11(2):155–61. doi: 10.1038/ni.1836 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Han K. An efficient DDAB-mediated transfection of Drosophila S2 cells. Nucleic Acids Res. 1996;24(21):4362–3. doi: 10.1093/nar/24.21.4362 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001;25(4):386–401. doi: 10.1006/meth.2001.1261 [DOI] [PubMed] [Google Scholar]
  • 61.Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990;29(45):10351–6. doi: 10.1021/bi00497a009 [DOI] [PubMed] [Google Scholar]
  • 62.Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105–11. doi: 10.1093/bioinformatics/btp120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511–5. doi: 10.1038/nbt.1621 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses. 1995;45(5):486–90. doi: 10.1016/0306-9877(95)90228-7 [DOI] [PubMed] [Google Scholar]
  • 65.Olofsson B, Page DT. Condensation of the central nervous system in embryonic Drosophila is inhibited by blocking hemocyte migration or neural activity. Dev Biol. 2005;279(1):233–43. doi: 10.1016/j.ydbio.2004.12.020 [DOI] [PubMed] [Google Scholar]
  • 66.Silva E, Au-Yeung HW, Van Goethem E, Burden J, Franc NC. Requirement for a Drosophila E3-ubiquitin ligase in phagocytosis of apoptotic cells. Immunity. 2007;27(4):585–96. doi: 10.1016/j.immuni.2007.08.016 [DOI] [PubMed] [Google Scholar]
  • 67.Revzin A. Gel electrophoresis assays for DNA-protein interactions. Biotechniques. 1989;7(4):346–55. [PubMed] [Google Scholar]
  • 68.Hawkins CJ, Wang SL, Hay BA. A cloning method to identify caspases and their regulators in yeast: identification of Drosophila IAP1 as an inhibitor of the Drosophila caspase DCP-1. Proc Natl Acad Sci U S A. 1999;96(6):2885–90. doi: 10.1073/pnas.96.6.2885 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Gregory P Copenhaver, Estee Kurant

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

17 Mar 2021

Dear Dr Xiao,

Thank you very much for submitting your Research Article entitled 'Bfc, a novel Serpent co-factor for the expression of Croquemort, regulates efferocytosis in Drosophila melanogaster' to PLOS Genetics.

Your manuscript has now been reviewed by three expert referees. These reviewers expressed major reservations and felt that more work was required to substantiate the conclusions drawn. In addition, some of the results need better explanation and re-evaluation of data, and the methods section and the figure legends must be re-written. English usage and grammar should be improved throughout the manuscript including the appropriate use of abbreviations.

We would like to re-consider a substantially revised version of the manuscript if the reviewers' concerns are adequately addressed. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our guidelines.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Estee Kurant

Guest Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: In their manuscript, Zheng et al. identify CG9129/Bfc as a gene required for proper expression of the apoptotic receptor Croquemort in Drosophila S2 cells and embryonic macrophages. Consistent with this observation, they found that Bfc loss is associated with a decrease in apoptotic cell phagocytosis. They further show that Bcf interacts with the GATA transcription factor Srp and their results suggest that Bfc could promote the direct binding of Srp to crq, thereby favoring crq transcription.

These findings are of potential interest but several conclusions are poorly substantiated. Importantly too, key controls and information are missing. Moreover, the level of analysis is rather limited and, in my opinion, beyond the expectations for PLoS Genetics.

Finally, the manuscript is poorly presented: several pieces of results are not well described or presented in a logical order, the figure calling is not accurate and the figure layout is often difficult to grasp, the text is plagued with typos and grammatical errors, and the “methods and materials” section is not appropriately written.

The comments below may help the authors to improve their manuscript.

Results sections:

- The authors should mention how many replicates were used for the RNAseq. Page 4: it does not make any sense to write that ±9000 genes (i.e. ±70% of the genes encoded by the genome) are differentially expressed at the different time points; differential expression must be defined with clear cutoff (fold change and p values, as used page 5).

- Page 5: “engulfing S2 cells displayed changes in multiple transcriptional programs”: where are the analyses /tables for such conclusion?

- Page 5 / Figure 2: the criteria used to select the 24 genes are not very clear; some genes that were kept/eliminated do not seem to strictly follow the threshold/statistical significance criteria (eg: PGRP-SA, CG12112…).

- How the author explain that several genes tested by RT-qPCR did not behave as in the RNAseq experiment ?

- Page 5 / Fig. 2c: it is not clear how efferocytosis efficiency is measured. Also the effect of crq knock-down seems very mild and it is thus questionable whether this assay is a good readout.

- Fig 2d: at which time point is crq expression assessed?

- Page 6/7: the parallel analyses for the two alleles of Bfc should be presented at the same time.

- Why is there more crq mRNA in stage 11 bfc null embryos (fig S3e)? This is not consistent with the author hypothesis.

- The legend is missing for Fig S3F.

- Figure 3a: the effect of Bcf RNAi on S2 cells AC engulfment is not quantified.

- Figure 3e: why is acridine orange staining so low in Bcf KO embryos?

- Page 7: the authors can not conclude that Bfc KO did not affect macrophage development. They should use other markers than Crq to quantify macrophage number / repartition. Actually, with Crq immunostaining (Fig 3f), it seems that there are less macrophages in the head region (and the level of Crq in each cell does not seem reduced as compared to control!).

- Page 8: “down-regulation of crq in the absence of Bfc caused the defect in AC clearance”: this is an important point that needs to be formally addressed. In addition to their data that support this hypothesis, the author should rescue Bfc KO by re-expressing Crq and assess AC clearance.

- Fig 4a: the author should show a higher magnification of Bfc immunostaining together with DAPI or another nuclear marker to demonstrate that Bfc is in the nucleus in vivo. The quality of the present image is clearly insufficient.

- Fig 4c: an important negative control is missing (IP with anti-Flag on S2 cells transfected only with HA-Srp). The authors should also try to perform the IP with anti-HA and with the endogenous Bfd (using the anti-Bfd).

- Fig S5d: this may not be “endogenous” Bfc in S2 cells since these cells are transfected with Bfc-FLAG.

- the immunostainings with Bcf and Flag antibodies in Fig S5d look very different from the one shown Fig 4d (GFP-Bfc). This casts doubt on the results. The immunostainings in 4d is very strange as Srp is not known to form such kind of foci. Again some negative controls are missing (single transfections + double immunostaining).

- Page 9 / Figure 5: the authors claim that single heterozygous did not show differences but these results are not shown/quantified. They must be shown.

- Page 9: the last paragraph is unclear and not connected with Srp/Bfc interaction.

- Page 10: the two-hybidrid experiments described here are not displayed Fig S5 but Fig S6. Moreover, there is a clear decrease in the binding of Srp to Bfc when the Cys are mutated to Arg.

- Page 10 / Figure 6: the authors claim that they assess Bfc and STAT92E (why?) binding to crq regulatory sequence but the data are not shown.

- Page 10/ last line: it is inaccurate to state that “crqM-Gal4 failed to activate transcription”. This driver is just weaker than crq-Gal4. In addition, the authors should test whether crqM-Gal4 activity is (still) affected by Bfc KO and/or srp KO.

- The ChIP experiments results are weird. Anti-HA ChIP with non-transfected S2 cells would be a better control. Also it is very unlikely that you can get around 40% of Srp ChIPed to crq as compared to input (even with Histones, people usually end up with a few % of efficiency).

- The EMSA experiments are ill-described and not performed properly (100% of the probe is shifted in the presence of GST-Srp). The evidence that Bcf promotes Srp binding are very weak. Bfc dose-dependant effect should be demonstrated in EMSA; and reciprocal experiments with Bfc knock-down should be performed. Also it should be checked by western blot that Srp level is not affected upon Bfc overexpression

TheM&M does not give sufficient details concerning many experiments. Notably:

- none of the plasmids used in the transfection assays are described.

- The RNAseq analysis is poorly described.

- The efferocytosis assays and quantification is not clearly presented.

- Details concerning the anti-Bfc antibody production are missing.

- The EMSA assays are not presented with sufficient details (eg: quantity of poly dIdC, fold excess for crq probe competition…).

- Protocols for nuclear extract preparation and coIP protocol are not given.

Other comments:

- The RNAseq data should have been deposited in a public database and a link provided for reviewer access if the data have not been released yet.

- the standard deviations for the control situations are apparently missing in several graphs (for example: Fig 1a, c, 1e, 2a, 2b, 2d, 2e, 5f, 6c…); it is thus impossible to evaluate the significance of the differences between control and test situations.

- It is generally accepted that figure calling follow their order of appearance in the main text, which is not always the case here (e.g.: Fig 3a, Fig 4c /d....).

- Some figures / part of figures are not presented in the text (for example figure 6d right panel).

- The arrangement of the panels could be improved to follow a more logical order and facilitate the interpretation by the reader. For example, Figure 2: the “positive” and “negative” genes could be displayed in 2a and 2b respectively and the order of the genes should be kept constant (alphabetical?) in the different panels. Figure 5: place the protein level quantifications below or beside the corresponding western blots and the phagotytic index graphs next to the corresponding images).

- It is customary to present lateral views of embryos dorsal side down.

- There is a number of recurrent typos; notably: space missing between word and bracket when citing a paper, um instead of µm, CHIP instead of ChIP.

- The material and methods sections should be rewritten more clearly, not as a lab protocol, and taking care of correcting grammatical errors as well as scientific mistakes (example: DNA primers do not have a N-terminal but a 5’)

Reviewer #2: Zheng et al describe a new regulator of efferocytosis in Drosophila, bfc. Bfc physically and genetically interacts with the GATA factor Serpent, a key transcription factor used in specification of Drosophila blood cells. Bfc was identified via transcriptional profiling of S2 cells treated with dying cells in vitro. A number of other interesting genes that are modulated via exposure to apoptotic cells are described but not followed up further and these too will be interesting to the field.

A subset of these genes regulate levels of croquemort, a gene initially identified on the basis of a role in apoptotic cell clearance. From these genes Bfc is characterised further and shown to regulate crq at both the mRNA and protein level. Bfc interacts with Serpent in vitro and within cells and there are convincing genetic experiments showing that it plays a role in Crq levels in vivo. The authors suggest Bfc acts as a co-factor of Serpent to promote Crq expression in response to macrophages facing apoptotic cells. The data suggest that Serpent regulates crq expression via a GATA site in the crq promoter. Less clear is the exact mechanism via which Bfc exerts its effects and I think that part of the manuscript needs to be improved.

The paper is very interesting and contains significant amounts of work. However, further work is required to strengthen and support the conclusions that have been made, although many of my comments can be addressed with careful re-writing or re-analysis. The manuscript also needs substantial work to aid the reader in following the manuscript and to ensure reproducibility. Please see my detailed comments below. I hope the authors will not feel disheartened by the number of comments I have made as I feel generally they should be fairly easy to address and the majority do not require further experiments to be carried out.

Major points

--------------

1. I am afraid that I found the manuscript hard to follow in many places. The figure legends and methods are insufficiently detailed and in many places the results are not described well enough to follow what has been done. The methods are written in a note form that is closer to a protocol than the methods section of a publication. Therefore, the entire manuscript would benefit from careful rewriting to ensure sufficient detail is included to aid the reader. This is particularly the case in the section relating to Figure 6 and 7. Additionally, in some places the language used is not grammatically correct or could be improved to help understanding.

2. The statistics section in the methods is too brief and it appears that inappropriate statistical analyses have been used in many of the figures: according to the methods section it seems that multiple t-tests have been used to compare >2 experimental conditions. Details of the statistical tests used are not described in the figure legends. Therefore, all numerical data and the statistical tests used to compare experimental groups need careful checking and (if needed) a different statistical analysis performing. This may change whether certain data remains statistically significant, so conclusions may need to be modified.

3. While I am largely convinced that Srp and Bfc interact and that Srp is binding the crq promoter via a GATA site, I am not convinced that the mechanism by which Bfc is working with Srp is correct or supported by the data presented. This model and Figure 7 are not explained very clearly in the manuscript. I am not sure the data supports the idea that Bfc increases the amount of Srp bound to the crq promoter. However, the way in which the IP and EMSA data are described does not help the reader. Can the authors show that the presence or absence of Bfc regulate the interaction of Srp with the crq promoter (e.g. via ChIP)? For instance: P11 “Bfc interacts with the zinc-finger domain of transcription factor Srp as a co-factor to enhance Srp binding to the crq promoter to elevate its expression and induce efferocytosis in Drosophila melanogaster.” I am not sure that the EMSA data is consistent with this conclusion, but it is not adequately described in the manuscript.

Aditionally, it is not clear what the controls on the left of Fig 6d are or what the panel on the furthest right is demonstrating, as this is not explained anywhere. Authors claim an increase in the migration efficiency of the Srp-DNA complex in the presence of Bfc. Is this the very faint band that can just about be made out below the main band? If so, it is not clear what this means in terms of the mechanism and does not appear to be consistent with Bfc binding to the DNA in concert with Srp, as that should decrease mobility of the band. It is thus not clear how the interaction of Bfc with Srp is functioning to increase Crq levels from this data. Also, why is the Bfc + Srp condition repeated so many times on this gel?

On page 14: “Furthermore, Bfc-Srp interaction occurred through the ZnF GATA domain and that the presence of Bfc increased the ability of Srp to bind the crq promoter.” I don’t think this is substantiated by the data – if it refers to the slight increase in intensity in Fig 6d (not quantified) and this seems an inappropriate conclusion as there is not an excess of DNA (no free probe visible at the bottom). Therefore, probe is rate limiting for complex formation and so adding a fraction more in one lane would change intensity.

4. Authors claim to have analysed STAT92E, but no data is presented: “To detect the physical interactions between regulatory transcription factor proteins and crq in the genome, we then performed yeast one-hybrid (Y1H) assays(Reece-Hoyes and Marian Walhout, 2012) between Bfc, Srp, Stat92E, and the crq promoter locus, respectively.”

5. Apoptotic cell clearance is only analysed in the head. Can defects in apoptotic cell clearance be detected elsewhere in the embryo in bfc mutants? Dcp-1/Crq staining is only shown for the head region. Acridine orange staining looks like it may be less affected in the absence of Bfc along the ventral regions of the embryo. This is particularly important due to the emerging idea that different subtypes of macrophage may be present in the fly (e.g., Cattenoz et al., 2020; Tattikota et al., 2020).

6. Is anti-Crq the best marker to stain and visualise macrophages accurately in bfc mutants if Crq protein levels are so decreased in the absence of Bfc (Figure S5c and other similar figures)? I have always found it difficult to see how phagocytic index is accurately measured using anti-Crq staining in comparison to, for example, use of srpHemo-GAL4,UAS-GFP and other such tools; it is hard to see where one cell begins / ends and how many cells are present in these images. It is also hard to see what is going on due to the overlap of red and green staining in these images (can single channel images be displayed with the merge?) Also, please consider using green/magenta rather than green/red due to those suffering from colourblindness, especially if separate channels are not to be displayed. What do the white dotted circles represent? Individual cells? Lastly, the use of anti-Crq makes it difficult to score these images blindly as mutant and wt/rescues can easily be discriminated and this appears to be quite subjective scoring anyway (precise details are missing from the methods). N.b., these comments apply to all figures that show anti-Crq/anti-Dcp-1 staining.

7. Figure 4d shows Bfc is nuclear in S2 cells. Can a nuclear marker/dye and higher magnification imaging show a similar localisation in macrophages in the embryo? What happens to Srp localisation on RNAi of Bfc from S2 cells? This should be fairly easy to do with the reagents already in hand and may give an insight into how the Bfc-Srp interaction works to regulate Crq levels (especially as I am not sure about the EMSA data).

8. Why are immune genes like cecropin coming up in the transcriptional profiling? This seems counterintuitive to the silent clearance of apoptotic cells, as it suggests immune activation. We ourselves have had issues generating apopototic cell samples via similar methods – we obtain apoptotic cells but also a large amount of necrotic cells. The AC samples used/method therefore require characterisation/validation (e.g., caspase activity probes, annexin, PI – all widely available). It therefore is possible that some of the genes that are being upregulated are in response to necrotic cells present in the samples in addition to the apoptotic ones. The AC samples should be characterised and if necrotic cells are present the conclusions need to be modified to acknowledge that the transcriptional changes observed may not be specific to contact with apoptotic cells.

9. In general, the discussion needs to discuss the findings in a broader context, as it mostly simply repeats the conclusions/findings of this paper. In particular there is barely any discussion of the work in relation to other organisms (only 1 mammalian paper is cited). For instance, do homologs of Bfc exist in vertebrates? Is this a fly specific mechanism? A careful re-write of this section will make it much more appealing and relevant for non-Drosophilists.

Minor comments

------------------

1. Figure 1d-e what does % phagocytosis mean? I presume % of S2 cells phagocytosing AC – please make clearer in legend and methods.

2. I am not sure that it is possible to make the conclusion that “as an engulfment receptor, Crq contributed to early recognition of ACs, while engulfment at later stages likely depended on other regulatory factors to mediate further AC clearance.” It is not clear whether the internalised AC were internalised at earlier times and have not yet been degraded or have been internalised more recently. In my opinion to test this properly you would need to stimulate with AC, remove excess AC and then challenge again, or something similar (if this was actually how the experiment was carried out it is not clear from the results, methods or figure legend). I don't propose this experiment is repeated as suggested, as this doesn't seem a key point, just that the conclusions are modified.

3. What are the experimental conditions for Figure 2c,d? This is not clear from the text, methods or legend. I presume this is with AC treatment, but for how long etc?

4. The effect of knockdown of CG9129/bfc is far stronger than for crq itself (Figure 2c), what other processes may be affected given bfc seems to play no role for SIMU and drpr? It may be nice to speculate on this in the discussion.

5. Figure 3a appears after Figure 3c-d. Authors may want to reorder the text / figure slightly to improve how the manuscript reads. There are quite a few panels not cited (e.g. Fig S3e) in the text or mistakes in which figures are being cited throughout the manuscript.

6. Not all of the inset can be seen in the main field of view for the central panel of Figure 3a, while the zooms could have been a bit bigger. I also struggled to see where the regions were taken from (in fact I am unable to see where the zoom for bfc RNAi came from at all for that field of view).

7. Please provide details of how the mouse anti-Bfc was generated (what epitope was used etc). Authors should check for other methods that are not described in the paper.

8. Figure 4a - why is the green channel so bright in the bfc[ko] embryo? Have these embryos been imaged using the same settings/enhanced similarly? Why is the green channel so faint in the boxed region of the bfc[ko] panel compared to the main image? Individual channels should be shown and advisable to use magenta in place of red for merges. Also, it would be better not to inset zoomed regions over the posterior of the embryo as this prevents the reader from analysing expression in posterior macrophages.

9. References required for this statement on p8: “Previous researches have demonstrated that several signal pathways regulated the expression of engulfment receptor Drpr, such as d-JNK, PI3K and insulin.”

10. page 10 – some confusion / mix ups for figure labelling for Figures S5-7. Not all panels are cited in the text.

11. Why does bfc not work to regulate the amounts of other Srp-dependent receptor genes? Authors suggest other co-factors regulate Srp’s activity at the drpr and simu promoters but I don’t think their model is sufficient to explain why Bfc would not assist at those promoters given their regulation by Srp. Perhaps it would be clearer with more explanation?

12. P13 “These results imply that the expression of phagocytotic receptors could be stimulated by the presence of excessive ACs to improve the phagocytotic activity of macrophages.” This has been shown by a number of other labs in the fly (e.g., Wood and McCall) in flies and is well-documented in vertebrates. These and other papers should be cited and this new mechanism contrasted with how this is regulated in other systems.

13. Authors may wish to include Han et al. (2014) and Guillou et al. (2016) in the discussion since these suggest functions for Crq other than a role as a receptor for apoptotic cells.

14. Supplemental tables 3 and 4 are not cited in the manuscript.

Reviewer #3: The review is uploaded as an attachment.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: No: No GEO accession number/link to a public database was provided for the RNAseq data. None of the values used to build the graphs were provided as supporting information.

Reviewer #2: No: I am not sure that the RNAseq data has been or will be uploaded to a public repository. It should be uploaded on acceptance with the location contained within the paper in the final published form. Numerical data not supplied in current submission.

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Attachment

Submitted filename: Zheng et al. Bfc Review.pdf

Decision Letter 1

Gregory P Copenhaver, Estee Kurant

7 Jul 2021

Dear Dr Xiao,

Thank you very much for submitting your revised version of the Research Article entitled 'Bfc, a novel Serpent co-factor for the expression of Croquemort, regulates efferocytosis in Drosophila melanogaster' to PLOS Genetics.

The manuscript was fully evaluated again at the editorial level and by three independent peer reviewers.  Two of them now ask minor revision whereas Reviewer #1 requests additional experimentation which the editors agree is necessary to support the central conclusions of the study. In addition, English usage and grammar still need improvement throughout the manuscript - we find that authors often benefit from having their manuscripts proof read by a native English speaking colleague, or by using a reputable copy editing service.  

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Estee Kurant

Guest Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: In their revised manuscript, Zheng et al. have answered some of the concerns raised by the 3 referees and have improved the overall quality of their work. Yet, beside the presentation of the data and M&M that needs to be improved, several conclusions are not well substantiated and some experiments are still not performed adequately. In addition, some of the modifications introduced during the revision do not speak in favor of a rigorous analysis of the results by the authors.

Thus, even though the authors made important modifications to their manuscript, I still think that it does not reach the standards of quality expected for publications in PLoS Genetics.

Some specific comments to the authors.

Major points:

- The statistical significance of many results shown in Figure 2 and S1 have changed as compared to the original version of the manuscript even though they are based on the same numerical data. While I understand that the authors have now used different methods (Annova), I’m very skeptical as some points “gained” one or even two stars of significance and other lost up to three stars!! (e.g: pgrpSA at 12h was “ns” and is now p<0.01; CG8907 at 6 and 12h were p<0.01 and are now ns!). This casts important doubts on the analyses of the data by the authors.

- The authors claim that bfc mutation does not affect macrophage development but the data are still not convincing (S4B-C). Notably, the authors used srp-GAL4>GFP to label macrophages and they observed around 100 macrophage per embryo in wildtype and bfc mutant contexts. This is far less than expected as wildtype embryos contains several hundreds of macrophages!

- The rescue experiment with crq-GAL4 UAS-Crq was performed in the hypomorphic bfc mutant and not in the null context (S6). As the authors showed that Crq induces bfc transcription, it is thus difficult to conclude that it the restauration of Crq level rather than the restauration of Bfc level which is responsible for the rescue.

- The impact of apoptosis/ACs on Srp/Bcf-mediated regulation of crq is not clearly assessed. Notably, the authors do not formally test that apoptosis is important for the induction of Bfc and/or Crq expression in vivo. Actually, line 213/FigS3B, the authors show that bcf expression is upregulated as early as stage 9, i.e. before the first wave of apoptosis (stage 11). The conclusion lines 235-236 is not substantiated by the in vivo data. The authors could use the H99 deletion to prevent apoptosis in the embryo and assess whether this affects bfc and crq induction. Thus far, the conclusion line 505-506 is not really sustained.

- The hypothesis that Bfc promotes Srp binding to crq regulatory region is still poorly substantiated. First, the results of the EMSA are not convincing: the supershift with Bcf/Srp is barely detectable and does not really increases with Bcf dose. The binding of Srp to crq probe seems highly variable (cf 2E and 2E’); it may increase with Bcf but this could reflect a mere stabilization due to increased protein concentration in the reaction (increased Srp binding is also observed when anti-HA antibody is added to the reaction in 2E’). Also, line 7 does not seem to contain any probe, and the competition with the unlabeled crq probe does not seem to work in panel 2E. Second, the authors did not test the influence of Bfc on Srp recruitment to crq region by ChIP and they did not assess whether Bfc over-expression/knock-down affects Srp protein level (by western blot). Again these experiments (ChIP, luciferase assays, western blots) should be performed in S2 cells exposed to ACs to be able to conclude on the molecular mechanisms by which ACs control crq expression (lines 469-470).

Minor points:

- Lines 120-123: I don’t see a particularly logical link between ACs clearance and bacteria uptake. Even if there is one, the level of Crq is lower at 12h than at 6h but efferocytosis is higher at 12h

- In the discussion: lines 550-552 and 562-565 are identical.

- Lines 560: references are missing concerning the regulation of crq by Srp. Also, when discussing the role of Ush/Srp (lines 538-541): the induction of crq by Srp was shown to be repressed by Ush in Waltzer et al EMBO J 2002.

- Some parts of the material and methods are still written in a note form closer to a protocol than the methods sections of a publications (e.g.: lines 697-699; 723-728; 746-751; 758-770; 778-779

- I did not find the GO annotations data for the RNA-seq in the supplemental data (lines 649).

- It is still not clearly mentioned in the M&M that the authors generated not only a crqM-GAL4 but also the crq-GAL4 “wildtype” version, integrated at the same site an in the description of the results/figure legends, it should be clearly mentioned when the authors use Bloomington crq-GAL4 or their crq/crqM-GAL4 lines.

- In their answer to reviewer 1, the authors claim that they could not recombine crqM-GAL4 with bfc or srp; yet according to their M&M crqM-GAL4 is on chromosome II, so it shouldn’t be a problem. And if it is on chr III, it should be possible to obtain recombinant at least with one of the two genes (bfc or srp) as they are on opposite chromosomal arms.

- Figure 4D: the negative controls (right panel) should have been performed in the same experiment and not added afterward to the original coIP (left panel).

- Figure S7C: part of the anti-HA western blot (lanes HA-Srp4) is visibly spliced from another gel.

- Many typos need to be corrected (e.g.: line 19: Srp shouldn’t be in italic, line 34: (ACs) => ACs; line 41: induce => induces…).

Reviewer #2: Uploaded as an attachment.

Reviewer #3: The review is uploaded as an attachment.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: No: Numerical data that underlies graphs are not provided.

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Attachment

Submitted filename: Reviewer 2 comments_Zheng et al_revision1.pdf

Attachment

Submitted filename: Zheng et al. Bfc Review 2.pdf

Decision Letter 2

Gregory P Copenhaver, Estee Kurant

29 Oct 2021

Dear Dr Xiao,

Thank you for submitting your revised version of the Research Article entitled 'Bfc, a novel Serpent co-factor for the expression of Croquemort, regulates efferocytosis in Drosophila melanogaster' to PLOS Genetics.

The manuscript was fully evaluated again at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some concerns that we ask you address in a revised manuscript

We therefore ask you to modify the manuscript according to the review recommendations. Your revisions should address the specific points made by each reviewer.

In addition we ask that you:

1) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our archive. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Estee Kurant

Guest Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The authors significantly improved their manuscript and addressed my main concerns.

I may have missed it but I didn't find an accession number to a public repository for the RNA-seq data. This should be provided.

Reviewer #2: The authors have satisfied all my comments and (in my opinion) have done a good job of answering the other reviewers's comments.

The manuscript is now far easier to read and the conclusions are more robust with the additional new data. The figures are much improved and more robust. Areas in which the paper was less strong have now been significantly improved (methods, presentation of gels/legends/descriptions, statistics).

Some typos remain and the manuscript should be proofed carefully. I list some errors I found while re-reading the manuscript to help the authors (see below); It may be that the editing company changed the meaning a little in some places.

This is really interesting work and I look forward to hearing about the other hits they have uncovered via this approach.

Figure 4B-B’’’ – I suggest authors add annotation to these panels to indicate S2 cell / S2 cell / wt mac / bfcKO mac to help the reader.

Line 308 – says authors generated the insertion line, when materials and methods says this was obtained from Bloomington.

Line 336 “Bfc act as…” should read “Bfc acts as…”

Line 490 Misspelling - Bfs rather than Bfc

Line 581 indicate rather than indicating

Line 783 TRITC rather than RITC?

Reviewer #3: The review is uploaded as an attachment.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: No: I may have missed it but I didn't find an accession number to a public repository for the RNA-seq data. This should be provided.

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Lucas Waltzer

Reviewer #2: No

Reviewer #3: No

Attachment

Submitted filename: Zheng et al. Bfc Review 3.pdf

Decision Letter 3

Gregory P Copenhaver, Estee Kurant

15 Nov 2021

Dear Dr Xiao,

We are pleased to inform you that your manuscript entitled "bfc, a novel serpent co-factor for the expression of croquemort, regulates efferocytosis in Drosophila melanogaster" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Estee Kurant

Guest Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The authors have complied with the reviewers comments. Remaining typos can certainly be dealt with at the proof stage.

Reviewer #3: The review is uploaded as an attachment.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Lucas Waltzer

Reviewer #3: No

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: 

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-21-00197R3

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Attachment

Submitted filename: Zheng et al. bfc Review 4.pdf

Acceptance letter

Gregory P Copenhaver, Estee Kurant

29 Nov 2021

PGENETICS-D-21-00197R3

bfc, a novel serpent co-factor for the expression of croquemort, regulates efferocytosis in Drosophila melanogaster

Dear Dr Xiao,

We are pleased to inform you that your manuscript entitled "bfc, a novel serpent co-factor for the expression of croquemort, regulates efferocytosis in Drosophila melanogaster" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Agnes Pap

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. ACs were successfully generated from S2 cells, and the RNAi knockdown efficiency was confirmed by qPCR.

    A. S2 cells and ACs were stained with annexin V-FITC and propidium iodide (PI). Scale bar = 20 μm. ACs were obtained from S2 cells after Actinomycin D induction for 18 h, as described in the Materials and Methods section. B. The apoptosis rates of S2 cells and ACs were analyzed by flow cytometry. C. Western blotting detected the Dcp1 protein levels in S2 cells and ACs. Actin was used as the loading control. D. The relative mRNA levels of 24 genes in RNAi-treated S2 cell lines were quantified by qPCR and compared to those of control-treated S2 cells; RpL32 was used as the internal control. Statistical significance was assessed using the two-way ANOVA.

    (TIF)

    S2 Fig. CG9129 and crq regulate each other at the transcriptional level during the clearance of ACs in S2 cells.

    A. The CG9129 mRNA levels were quantified by qPCR in Crq-overexpressing S2 cells (Crq-GFP) and control S2 cells. The crq mRNA levels were also quantified by qPCR in CG9129 over-expressing S2 cells (CG9129-flag) and control S2 cells. 0 h refers to S2 cells in the absence of ACs; 6 h refers to S2 cells co-incubated with ACs for 6 h. RpL32 was used as the internal control. B. The CG9129 mRNA levels were also determined in RNAi-treated S2 cells (control and for the knockdown of crq) after co-incubation with ACs for 6 h, by qPCR. Statistical significance was assessed using the two-way ANOVA (A) or Student’s t-test (B).

    (TIF)

    S3 Fig. Bfc regulates the expression of Crq in vivo.

    A. The relative crq mRNA levels in stage 7–14 wild type embryos were quantified by qPCR; significant differences were observed compared to the expression in stage 7 embryos. B. The bfc mRNA levels in stage 7–14 wild-type embryos were quantified by qPCR; significant differences were observed compared to the expression in stage 7 embryos. C. The relative crq mRNA levels were quantified and compared in the same stage of wild type and bfcko mutant embryos by qPCR. D. Western blot analysis was used for the detection of the Crq protein levels in stage 11–14 embryos of wild type and bfc mutant flies. Actin was used as the loading control. E. The relative Crq protein levels in stage 11–14 wild type, and bfcko mutant embryos were analyzed via western blotting. The protein levels were normalized to those of actin. Significant differences were observed in comparison with stage 11 wild-type embryos; n = 3. F. The relative crq and bfc mRNA levels were quantified by qPCR in stage to 10–13 wild-type w1118 and H99 (absence of apoptosis) embryos. G. The crq, bfc, and drpr mRNA levels were quantified by qPCR and normalized to the Rpl32 mRNA levels. “*”/“#”/“※” represent the significant differences in the context of crq/bfc/drpr expression, respectively. “##” indicates P<0.01; “###” indicates P<0.001; “####” indicates P<0.0001; “※※” indicates P<0.01. H. The drpr mRNA levels were quantified by qPCR in wild-type S2 cells and bfc-RNAi S2 cells in the presence or absence of ACs. Statistical significance was assessed using the one-way ANOVA(A, B, E, F, H) or two-way ANOVA (C, G).

    (TIF)

    S4 Fig. bfc knockout reduced crq expression without affecting macrophage development in the embryos.

    A. The crq, drpr, and simu mRNA levels were quantified by qPCR in stage 13 wild-type, bfcko, and srp mutant embryos. B. Macrophages were stained with anti-CRQ (green) antibodies, and ACs were stained with anti-Dcp1 (magenta) antibodies in stage 13 wild-type and bfcko embryos. Scale bar = 20 μm. C. Graph showing the number of macrophages ± SEM for genotype of wild type, bfcko, srp-Gal4>UAS-GFP and bfcko; srp-Gal4>UAS-GFP. Statistical significance was assessed using the two-way ANOVA (A) or one-way ANOVA (C).

    (TIF)

    S5 Fig. Bfc is required for efferocytosis of embryonic macrophages.

    A. Z-stack of eight images from a single macrophage of wild type and bfcko embryos taken at intervals of 1 μm. Scale bar = 5 μm. B-B’. Control srp-Gal4>UAS-GFP embryo macrophages were labeled with srp-Gal4>UAS-GFP (green); anti-Dcp1 was labeled in magenta. C-C’. bfcko; srp-Gal4>UAS-GFP embryo macrophages were labeled as srp-Gal4>UAS-GFP (green); anti-Dcp1 was labeled in magenta. Scale bar = 20 μm. D. Graph showing the mean PIs ± SEM for each genotype (A-C). Statistical significance was assessed using the one-way ANOVA.

    (TIF)

    S6 Fig. bfcMI02020 mutants show a defective efferocytosis of ACs.

    A. The crq and bfc mRNA levels were quantified by qPCR using wild-type and bfcMI02020 embryos. B. Graph showing the mean PI ± SEM for each genotype in (C). C. Anti-CRQ (green) and anti-Dcp1 (magenta) antibodies were used to stain the apoptotic bodies in macrophages of stage 13 wild-type, bfcMI02020, and bfcMI02020 re-expressing UAS-bfc (under the control of a crq-Gal4 driver) embryos. The white arrowheads point to non-engulfed ACs. Scale bar = 20 μm. D. Anti-CRQ (green) and anti-Dcp1 (magenta) antibodies were used to stain the apoptotic bodies in macrophages of stage 13 wild-type, bfcko, and bfcko re-expressing UAS-crq (under the control of a crq-Gal4 driver) embryos. The white arrowheads point to non-engulfed ACs. Scale bar = 20 μm. E. Graph showing the mean PI ± SEM for each genotype in (D). F. Anti-CRQ (green) and anti-Dcp1 (magenta) antibodies were used to stain the apoptotic bodies in heterozygous macrophages of stage 13 bfcko/+ and srp/+ embryos. The white triangles point to non-engulfed ACs. Scale bar = 20 μm. Statistical significance was assessed using the two-way ANOVA (A) or one-way ANOVA (B, E).

    (TIF)

    S7 Fig. bfc and the crq promoter interact with the ZnF GATA domain of Srp.

    A. Schematic diagram showing the domains of Srp and the truncations generated to examine the potential Bfc-Srp interactions. B and C. The interaction between Bfc and Srp was examined using the yeast two-hybrid (B) and Co-IP assays (C). D. Schematic diagram showing the C4M mutants with the substitution of eight cysteines by arginines in the C4 motif of Srp. E. The yeast two-hybrid assay showing the interaction between Bfc and the C4M Srp mutant. F. The yeast one-hybrid assay shows the lack of interaction between the crq promoter C4M and the C4M Srp mutant.

    (TIF)

    S8 Fig. Mutations in the GATA site result in the weaker activation of Crq expression in Drosophila embryos.

    A. Anti-Flag (green) and anti-Dcp1 (magenta) antibodies were used to stain macrophages and ACs of stage 13 wild-type, bfc mutant re-expressing UAS-CrqFlag (under the control of a crq-Gal4 driver), and wild-type re-expressing UAS-CrqFlag (driven by mutated crq-Gal4) embryos. Scale bar = 20 μm. B and C. The Flag protein levels were determined via western blotting for each genotype in (A). Actin was used as the loading control. D. Quantification of the Flag protein levels in (B) and (C) after normalization to those of actin (n = 3). E. The Crq protein levels were detected via western blotting in the context of w1118, bfcko, bfcko mutant re-expressing UAS-CrqFlag (driven by crq-Gal4), and wild-type re-expressing UAS-CrqFlag (driven by crq-Gal4) samples. Actin was used as the loading control. F. Quantification of the Crq protein levels in (E) after normalization to those of actin (n = 3). Statistical significance was assessed using the Student’s t-test.

    (TIF)

    S9 Fig. Bfc activates crq promoter to drive GFP protein through the GATA site in Drosophila embryos, while Bfc has no influence on Srp level.

    A-A”. Anti-GFP (green) and anti-Dcp1 (Red) antibodies were used to stain macrophages and ACs of stage 13 embryos in crq-Gal4>UAS-GFP(A), crqM-Gal4>UAS-GFP(A’), and crqM-Gal4>UAS-GFP; bfcko(A”). Scale bar = 20 μm. B. The GFP protein levels were determined via western blotting using crq-Gal4>UAS-GFP, crqM-Gal4>UAS-GFP, and crqM-Gal4>UAS-GFP; bfcko embryos. Actin was used as the loading control. C. Quantification of the protein levels in (B) after normalization to actin; n = 3. Statistical significance was assessed using the Student’s t-test. D. The Crq and Srp protein levels were determined via western blot analysis in blank, Bfc-overexpressing, and bfc-RNAi-treated S2 cells in the presence or absence of ACs. Actin was used as the loading control. E. Quantification of the protein levels in (D) after normalization to actin; n = 3. Statistical significance was assessed using the one-way ANOVA(C) and two-way ANOVA(E).

    (TIF)

    S10 Fig. The yeast one-hybrid assay revealed that Srp and Stat92e bind to the crq promoter and drpr promoter, respectively.

    A. Schematic diagram showing the domain of the crq promoter used for the yeast one-hybrid assay. B. The yeast one-hybrid assay shows the interactions between Srp-AD, Bfc-AD, Stat92e-AD, and the crq promoter. C. Schematic diagram showing the domain of the drpr promoter used for the yeast one-hybrid assay. D. The yeast one-hybrid shows the interactions between Srp-AD, Bfc-AD, Stat92e-AD, and the drpr promoter.

    (TIF)

    S1 Data. Differentially expressed genes from comparisons of 6h versus 0h, 12h versus 0h, and 6h versus 12 h, respectively.

    (XLSX)

    S1 Table. RNA-seq data of the 50 filtered genes.

    Representative genes were selected across a range of expression levels.

    (DOCX)

    S2 Table. qPCR primers used to obtain the data represented in Fig 2.

    (DOCX)

    S3 Table. dsRNA primers used to obtain the data represented Fig 2.

    (DOCX)

    S4 Table. Recombinant DNA constructs used in this study.

    (DOCX)

    S5 Table. Raw data for the statistical graphs used in all figures.

    (XLSX)

    Attachment

    Submitted filename: Zheng et al. Bfc Review.pdf

    Attachment

    Submitted filename: bfc response to reviewer 6.10.docx

    Attachment

    Submitted filename: Reviewer 2 comments_Zheng et al_revision1.pdf

    Attachment

    Submitted filename: Zheng et al. Bfc Review 2.pdf

    Attachment

    Submitted filename: response_to_reviewers_21.9.25.docx

    Attachment

    Submitted filename: Zheng et al. Bfc Review 3.pdf

    Attachment

    Submitted filename: response_to_reviewers_21.11.08.docx

    Attachment

    Submitted filename: Zheng et al. bfc Review 4.pdf

    Data Availability Statement

    All RNAseq data files are available from the NCBI SRA database (accession number PRJNA733098). The URLs is https://www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA733098 All other data is available within the paper and its Supporting Information files.


    Articles from PLoS Genetics are provided here courtesy of PLOS

    RESOURCES